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Abstract 
According to the World Health Organization (WHO), cancer is one of the leading 
causes of mortality. Side-effects are often complained by patients undergoing 
chemotherapy as the first-line treatment. Together with the increasing incidence of 
multidrug resistance (MDR) after prolonged treatment observed in recent years, novel 
cancer therapies with higher selectivity are of research interest. Photodynamic therapy 
(PDT) is an emerging approach for cancer treatment which involves the synergistic effect 
of two non-toxic elements, photosensitizer and visible light. Pheophorbide a (Pa), an 
active component isolated from the traditional Chinese medicine Scutellaria barbata in a 
bioassay guided approach by our group, exhibits photodynamic activity and has been 
reported cytotoxic upon photo-activation in several types of tumor cell lines. 
In this study, the mRNA expression levels of growth arrest and DNA damage 
inducible genes GADD34, GADD45A, GADD45G and GADD153 were found to be 
increased after Pa-mediated photodynamic therapy (Pa-PDT) on human breast tumor 
cells MCF-7, while the expression level of GADD45B gene was not affected. A time and 
dose-dependent G2/M phase cell cycle arrest was observed 24 h onwards after Pa-PDT 
while the dose-dependent sub-Gi population dominated the cell cycle profiles at 72 h 
•• 
after Pa-PDT. Protein levels of cyclin B1 and D1 were decreased by Pa-PDT treatment 
dose-dependently, while the levels ofcyclin A and E were not significantly affected. 
i 
The establishment of a multidrug resistance (MDR) breast tumor cell line was 
attempted by repeated doxorubicin (Dox) exposure to the estrogen receptor negative 
parental cell line MDA-MB-231 (MDA). Ten rounds of Dox exposure resulted in 3 fold 
increase in IC50 value, reduced intracellular Dox accumulation and mild up-regulation of 
P-glycoprotein (P-gp) mRNA level. The acquisition of Dox resistance did not confer the 
resistance to Pa-PDT, as the cytotoxicity of Pa-PDT and Pa uptake were demonstrated 
similar in both MDA and MDA-R cells. It indicated that Pa-PDT was able to circumvent 
drug resistance in mildly doxorubicin (Dox)-resistant human breast tumor cells MDA-R. 
The therapeutic potential of combination therapy with Pa-PDT and Dox was also 
n 
evaluated. The combination regimen was shown to be synergistic in P-glycoprotein (P-gp) 
over-expressing MDR uterine sarcoma cell line Dx5 but not in the parental, 
drug-sensitive cell line SA. Experiment with P-gp substrate Rhodamine 123 and 
propidium iodide co-staining on Dx5 cells after Pa-PDT treatment showed that Pa-PDT 
attenuated P-gp activity in a dose-dependent manner without severe damage to plasma 
membrane integrity of the cells. The synergism and P-gp inhibition were attenuated by 
a-tocopherol, a reactive oxygen species (ROS) scavenger. It was suggested that Pa-PDT 
inhibited P-gp activity via ROS generation in Dx5 cells and thereby sensitized them 
towards the cytotoxicity ofDox, resulting in synergistic interaction with Dox. As the cell 
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1.1 Cancer epidemiology and managements 
According to the World Health Organization (WHO), cancer is one of the 
leading causes of mortality worldwide. Cancer refers to a class of disease 
characterized by the uncontrolled proliferation of cells with the ability to metastasize. 
In 2007, 7.9 million people died of caner, accounting for around 13% of all deaths 
worldwide. The number was predicted to increase significantly in the coming 
decades, with an estimated 12 million deaths from cancer by year 2030. The leading 
cause of cancer mortality includes lung, stomach, colorectal, liver and breast cancers. 
»i 
I. Classification of cancer 
According to the International Classification of Diseases for Oncology (third 
edition), cancers can be grouped into six major categories from histological 
standpoints, including carcinoma, sarcoma, myeloma, leukemia, lymphoma and 
mixed types. 
Carcinoma is the most common type of cancers, accounting for 80-90% of all 
cases. Carcinomas are of epithelial origin, and they can be divided into two major 
subtypes, including adenocarcinoma which develops in glands and squamous cell 
carcinoma which originates from the squamous epithelium. Sarcomas are cancers 
originated from supportive and connective tissues such as bones, tendons, cartilage 
2 
and muscle. Myeloma is the cancer of plasma cells, which are immune cells found in 
the bone marrow responsible for antibody production. Leukemia, also known as 
liquid cancer, is the cancer of bone marrow manifested as the overproduction of 
immature white blood cells. Lymphoma refers to the solid tumor develops in the 
glands or nodes of the lymphatic system, including vessels, nodes and organs (such 
as spleen, tonsils and thymus). Examples of mixed types include carcinosarcoma, 
adenosquamous carcinoma and mixed mesodermal tumor. 
II. Conventional cancer treatments 
•• 
The ultimate goal of cancer treatment is the complete removal of cancer cells 
with minimal damage to normal tissues. The choice of therapy employed varies with 
the location, size and stage of the tumor diagnosed while major conventional 
treatments include surgery, chemotherapy, radiation therapy, and hormonal therapy. 
Surgery refers to the physical excision of the tumor together with the adjacent 
tissues and lymph nodes. However, surgical resection is not applicable for 
metastasized solid tumors and liquid cancers such as leukemia. Chemotherapy 
involves the systemic administering of cytotoxic drugs that kill the rapidly 
proliferating cancer cells. As a systemic treatment, chemotherapy is applicable for 
metastasized and liquid cancers. However, side-effects including nausea, reduction of 
3 
appetite, hair loss and bone marrow destruction are commonly experienced by 
patients. Moreover, the clinical effectiveness of chemotherapy may be limited by the 
development of multidrug resistance (Longley and Johnston 2005). In radiation 
therapy, cancer cells are either killed directly or prevented from proliferating by 
high-energy radiation, which can cause DNA damage and ionization of cellular 
molecules. Hormonal therapy involves the administering of exogenous hormone 
analogues or enzyme inhibitors to block the endogenous hormone production. It is 
only effective towards hormone-responsive cancers, for example breast, prostate and 
adrenal cortex cancers. 
•* 
In spite of the long history of implementation, conventional cancer therapies 
have their own drawbacks and clinical limitations. In particular, side-effects caused 
by the indiscriminative cytotoxic properties and the incidence of multidrug resistance 
(MDR) during chemotherapy pose great challenges in clinical cancer management 
(Longley and Johnston 2005). Thus, the development of more efficacious and 
selective cancer treatment is of research interest. Some of the novel strategies are 
discussed below. 
III. Novel cancer treatments 
I '• ‘ - •__•*"~ _.- «• 
Attributed to the understanding of molecular biology and carcinogenesis, 
significant advances have been made in cancer therapy during the last decades (Ma 
• 
4 
and Adjei 2009). Extensive research has been done to establish cancer treatments 
with higher selectivity. Novel therapeutic approaches including the use of 
monoclonal antibodies, small molecule inhibitors, anti-angiogenic agents and 
photodynamic therapy have been shown effective in cancer control clinically. 
Monoclonal antibodies 
Since the first introduction in 1986, more than 10 monoclonal antibodies were 
approved by FDA for cancer treatment (Gerber 2008). Monoclonal antibody offers 
high target specificity by recognizing and binding to its complementary antigens. 
Anti-cancer effects can be exerted through different mechanisms, for instance by 
0» 
recruiting host immune modulators to attack the target cells, binding to certain 
ligands or receptors, thereby interrupting cellular processes, or the antibody can be 
conjugated to a lethal agent, such as a radioisotope or toxin, thereby delivering to the 
target cell upon binding (Adams and Weiner 2005). 
Small molecule inhibitors 
Small molecule inhibitors typically interrupt cellular processes by interfering 
with tyrosine kinases-mediated signal transduction pathways including the human 
epidermal growth factor receptor (HER) family, insulin-like growth factor receptoK. 
(IGFR) family and phosphoinositide 3'-kinase (P13K) pathway (Ma and Adjei 2009). 
Upon tyrosine kinase activation, a cascade of molecular events will be elicited to 
. 
5 
cause cell growth, proliferation and migration. Imatinib is an effective small 
molecule inhibiting the continuously active tyrosine kinase resulted from 
chromosome translocation. Imatinib demonstrated complete hematologic response in 
98% of chronic myeloid leukemia patients (Kantarjian et al. 2003). 
Anti-ansiosenic asents 
It was observed that tumors are unable to grow beyond 2 mm^ without vascular 
support (Folkman 1971). Therefore angiogenesis, which refers to the formation of 
new blood vessels from the existing vasculature, is required for tumor growth. 
Vascular disrupting agents, small molecules inhibitors and monoclonal antibodies 
“ 
against vascular endothelial growth factor receptor are potential candidates in cancer 
therapy (Hicklin and Ellis 2005). 
Photodynamic therapy 
Photodynamic therapy (PDT) was developed progressively as anti-cancer 
modality in recent years. Upon visible light irradiation of the photosensitizer 
accumulated in the cancerous tissues, reactive oxygen species will be generated to 
mediate cell death. PDT is widely accepted as selective cancer therapy with the 
absence of severe systemic side-effects (O'Connor et al. 2009). As the focus of the.. 
present study, the mechanism involved and clinical advantages of PDT will be 
discussed in further detail below. 
• 
6 
1.2 Photodynamic therapy (PDT) as cancer treatment 
At the end of the 19山 century, Nobel laureate Niels Finsen found that light 
exposure was effective in treating smallpox and cutaneous tuberculosis. He named 
the use of light in treating disease "Phototherapy". Later Herman Von Tappeiner 
treated skin tumors by locally applying eosin and then irradiation by white light. He 
described such phenomenon "Photodynamic therapy", as the dynamic interaction 
involving light, photosensitizer and oxygen results in tissue damage (Dolmans et al. 
2003). 
Photodynamic therapy (PDT) involves the combination of two individually 
non-toxic components, a photosensitizer and light, to induce its cellular effects in an 
oxygen-dependent manner. In the first step of PDT, the photosensitizer is 
administered to the patient either locally or systemically. After a delay for achieving 
optimum bio-distribution, the lesion site is irradiated. Absorption of light by the 
photosensitizer will in turn initiate photochemical reactions to generate cytotoxic 
agents that result in the desired therapeutic effect (Wilson and Patterson 2008). 
Clinical application of PDT in solid tumors and pre-cancerous lesions found in 
skin, lung, esophagus, bladder and other organs has been either established (approved 
«« 
by governments) or under active clinical trials. Other than cancer modality, PDT is 
also effective in treating age related macular degeneration, psoriasis, actinic keratosis 
• 7 
and localized bacterial or fungal infection (Brown et al. 2004; Maisch 2007; Mennel 
et al. 2007). 
I. Mechanisms of photodvnamic therapy 
In general, reactive oxygen species (ROS) is generated upon the irradiation of 
photosensitizers. Intracellular ROS will thereby induce cell death, vasculature 
damage or immune response to accomplish the therapeutic effect of PDT. 
Upon irradiation with suitable wavelength, the photosensitizer is promoted from 
its ground state (So) to the first excited singlet state (Si). Further electronic transition 
converts the Si state photosensitizer into its longer-lived triplet state-(Ti). The Ti 
state photosensitizer can induce chemical changes in the neighboring molecules via 
Type I or Type II photochemical reaction. In Type I reaction, electron or hydrogen 
ion is transferred from the Ti state photosensitizer to oxygen or other adjacent 
molecules to form an anionic or cationic radical, such as superoxide anion and 
hydroxyl radical. Type II reaction occurs when energy (but not electrons) is 
transferred to molecular oxygen to form the non-radical but highly reactive singlet 
oxygen ('O2). The free radicals and singlet oxygen formed are collectively known as 
_ 
reactive oxygen species (ROS). Type I and II reactions occur simultaneously, while 
the ratio depends on the nature of photosensitizer used and intracellular oxygen level. 
• 8 
For most photosensitizers employed in PDT under normal physiological conditions, 
Type II reaction is predominant and single oxygen is the primary cytotoxic agent 
causing cellular damage. (Dolmans et al. 2003; Buytaert et al. 2007; O'Connor et al. 
2009; Plaetzer et al. 2009). A schematic illustration of the above excitation 
mechanism is shown in Figure 1.1. 
Three main mechanisms are involved in PDT-mediate tumor destruction. Firstly, 
ROS generated by PDT can directly induce cancer cell death. Secondly, PDT can 
damage tumor vasculature, leading to tumor infarction for long-term tumor control. 
Thirdly, immune response against tumor cells can be elicited after -PDT via the 
activation and infiltration of lymphocytes and macrophages into PDT-treated sites. 
(Dolmans et al. 2003; Buytaert et al. 2007; O'Connor et al. 2009) 
II. Advantages of photodynamic therapy as cancer modality 
Photodynamic therapy offers several promising advantages over conventional 
therapies in cancer management. Some of the clinical advantages of PDT are 
summarized from several review articles and discussed below (Hopper 2000; Wilson 
•• 
and Patterson 2008; O'Connor et al. 2009). . 
• 9 
Dual selectivity 
Certain photosensitizers demonstrate tumor specificity, and its photo-activation 
can be limited to lesion area by confining the location of irradiation. The dual 
selectivity of PDT offers minimal systemic side-effects often encountered in 
chemotherapy. Compared with conventional cancer treatments, PDT demonstrated 
lower morbidity and negligible damage to surrounding functional tissues clinically. 
Minimally invasiveness 
As PDT is a minimally invasive treatment and the effect is predominantly 
superficial, it can be used in the treatment of large area, for instance the pleura and 
peritoneum, where curative radiation cannot be tolerated. With the aid of interstitial 
light delivery system, light can be fed directly into solid tumors to potentiate the 
application of PDT in large, buried tumors in alternative to extensive surgical 
resection. 
Possibility of repeated and combined treatments 
PDT can be repeated at the same lesion site without inducing significant 
resistance or hypersensitivity. Moreover, PDT can be applied before or after surgery 
and radiotherapy, without abrogating the efficacy of these treatments or being 
attenuated itself. In particular, PDT is often applied to the tumor bed after the 
surgical resection of tumor as a sterilization procedure. 
. 10 
Involvement of multiple anti-cancer mechanisms 
PDT can trigger tumor destruction by directly inducing cell death, disrupting 
tumor vasculature and inducing immune response against cancer cells. It ensures the 
efficacy of PDT towards cancer cells with mutated pathway modulators, for example 
the down-regulation of pro-apoptotic proteins. 
Not mutagenic nature 
Most photosensitizers tends not to accumulate in the nucleus, therefore it is 
unlikely for PDT to induce DNA damage, mutations and carcinogenesis. In contract, 
radiation and chemotherapeutic drugs which work by interacting with DNA, are 
mutagenic in nature. The use of mutagenic modalities may increase the risk of 
secondary primary cancers (cancer not arising from the metastasized primary cancer) 
and development of multidrug resistance. 
II. Criteria of an ideal photosensitizer 
In the development of novel photosensitizers, several considerations should be 
fulfilled in order to ensure the clinical efficacy of PDT. The characteristics of an ideal 
photosensitizer are summarized from several review articles and discussed below. 
•• 
(O'Connor et al. 2009; Plaetzer et al. 2009) . 
‘ 11 
Photophvsical property 
The wavelength for maximum absorption should correspond to the therapeutic 
window between 650 nm and 850 nm. Within this range, tissue penetration is high 
while the energy of the triplet state is sufficient for singlet oxygen formation. A high 
quantum yield and long-lasting triplet state usually guarantee efficient production of 
reactive oxygen species(Plaetzer et al. 2009). 
Chemical property 
The photosensitizer should be a single pure substance of known composition 
and is stable at room temperature. The molecule is preferred to be amphiphilic, in 
order to ensure both transportation in blood and penetration through the plasma 
membrane without the formation of aggregates. 
Toxicity 
The photosensitizer should possess minimal dark toxicity, meaning that the 
toxicity should be very low in the absence of light, while the cytotoxicity can be 
highly elevated by light irradiation to guarantee anti-cancer efficacy. Moreover, the 
photosensitizer should generate no toxic metabolites by photodegradation or cellular 
metabolism. 
•• 
Pharmacokinetic (ADME) pro file . 
The absorption, distribution, metabolism and excretion (ADME) should be 
“ 12 
optimal for clinical application. For example, the half-life of the photosensitizer 
should not be too long, otherwise it may cause prolonged photosensitivity in patients. 
In particular, the photosensitizer is preferred to accumulate selectively within tumors 
to restrict photo-induced damage to surrounding tissues. 
1.3 Pheophorbide a (Pa) as a photosensitizer for PDT 
I. Bioassay-guided isolation from Scutellaria barbata 
The traditional Chinese medicine Scutellaria barbata, or Ban Zhi Lian (半枝蓮） 
in Chinese, is a perennial herb natively distributed throughout southern China. The 
herb is commonly used as anti-inflammatory, anti-tumor and diuretic agents in 
Chinese medicine (Qu 1990). As a cancer modality, the herb is prescribed for cancers 
found in lung, digestive system, liver and breast in Chinese clinical practice (Qian 
1987). 
Pheophorbide a (Pa) was isolated as the most effective anti-cancer constituent of 
S. barbata in a bioassay-guided approach previously by our group (Chan et al. 2006). 
The molecular formula of Pa is C35H36N4O5 and it is a chlorophyll a metabolite 
formed by removing the magnesium ion and a phytly group by the action of 
•• 
chlorophyllase (Suzuki et al. 2009). The chemical structures of chlorophyll a and Pa 
are shown in Figure 1.2. 
“ 13 
Pa is a porphyrin photosensitizer in nature, meaning that its cytotoxicity can be 
enhanced by photodynamic activation. Pa can be activated with Xmax at 666 nm, 
which is longer than the FDA-approved photosensitizers Photofrin® and 
5-aminolevulinic acid-induced ptotoporphyrin IX, which exhibit Xmax of 630 nm 
and 635 nm respectively (ROder et al. 2000; Detty et al. 2004). As light with longer 
wavelength exhibits deeper tissue penetration, the longer A,max of Pa is potentially 
advantageous over the currently available photosensitizers by offering more in depth 
irradiation to the tumors (Busch et al. 2009). 
II. Anti-cancer effect -
Pa was originally isolated as the active component against human 
hepatocarcinoma cells via the induction of apoptosis previously by our group (Chan 
et al. 2006). As Pa is a photosensitizer, the photodynamic activity of Pa was later 
being investigated. The IC50 value of Pa alone or with light irradiation on 
hepatocarcinoma cell line Hep3B was found to be 25.7 ^M and 1.5 i^M respectively 
(Tang et al. 2006), indicating that the cytotoxicity of Pa was elevated remarkably 
upon photo-activation. 
•* 
The anti-cancer effect of pheophorbide a-mediated photodynamic therapy 
(Pa-PDT) has been demonstrated via the trigger of intrinsic apoptotic pathway in 
• 14 
several human cancer cell types including hepatocarcinoma cell line HepG2 and its 
multidrug resistant counterpart R-HepG2, leukaemia cell line Jurkat, uterine sarcoma 
cell line MES-SA and breast adenocarcinoma cell lines MDA-MB-231 and MCF-7 
(Lee et al. 2004; Tang et al. 2006; Tang et al. 2009; Tang et al. 2009). In particular, 
Pa-PDT was shown able to reverse P-glycoprotein-mediated multidrug resistance 
(MDR) in R-HepG2 cells via JNK pathway activation (Tang et al. 2009). MDR is the 
major obstacle to effective anti-cancer chemotherapy and the mechanism involved 
will be discussed in Chapter 3. The circumvention of MDR phenotype by Pa-PDT 
will be further investigated in this study. As breast and uterus are out-growing or 
hollow organ, cancers found in these organs should be applicable for PDT by easing 
the irradiation procedure. Therefore the anti-cancer potential of Pa-PDT on these 
cancers will be further evaluated. 
1.4 Aim of study 
The aim of this study is to further investigate the mechanism involved in the 
anti-proliferative effect of Pa-PDT on human breast adenocarcinoma cell line MCF-7, 
and to investigate the effect ofPa-PDT on multidrug resistant (MDR) cancer cells. 
‘ 15 
Irradiation 
Intracellular p J ^ ^ 
Accumulation f ^ W ^ 
⑩<^ ^ c^CT^y^ 
�� � r y p ^ O 0 ^ 
"^"""“^p ^^^^^^-""^^^ u ^ 
iF.uorescence ® ~ \ oLdat.ve stress _ p Repair/Survival 
抓 1 8 _ _ / > ^ @ - " Cellular Damage ^ _ ^811 Death 
® M ^ ^ ^ ® 
® S e ; 7 ^ % ^ 
Extracellular 螺 為 Intracellular 
Figure 1.1 The mechanism involved in the photo-activation of photosensitizers. 
Upon irradiation, the photosensitizer is excited to higher energy levels. The excited 
photosensitizers in turns yield free radicals or singlet oxygen via Type I or II reaction. 
The reactive oxygen species cause cellular damage, and in case the damage cannot 
be repaired, the cells will undergo death pathway. 
(Buytaert et al. 2007) « 
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Figure 1.2 The chemical structures of chlorophyll a and pheophorbide a. 
The figure shows the structures of (A) chlorophyll a and (B) pheophorbide a, a 
chlorophyll a derivative formed by removing the magnesium ion and a phytly group. 
(ROder et al. 2000) 
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Chapter 2 
The anti-proliferative effect of pheophorbide a-
mediated photodynamic therapy on human 





2.1.1 Cell cycle regulation 
The cell cycle consists of different phases with precise and perhaps overlapping 
regulations. The Gi (first gap) phase is a resting phase that follows the previous 
division and the cells are preparing for DNA synthesis. DNA replication occurs 
during the S (synthesis) phase. G2 is the second rest phase which cells continue to 
grow and prepare for mitosis. During M (mitotic) phase, chromosomes are 
segregated and the cell division is completed. After M phase, the cell can enter G| 
phase again, or they can enter the resting Go phase to constitute the non-growing, 
non-proliferating cells in the organisms (Bloom and Cross 2007). -
I. Cvclin-dependent kinase regulation 
The progression of cell cycle is strictly controlled by numerous mechanisms to 
guarantee correct cell division. One of the major regulatory mechanisms is 
contributed by cyclin and cyclin-dependent kinases activities (Kastan 2001). Cyclins 
are the regulatory subunits and cyclin-dependent kinases (CDKs) are the catalytic 
subunits of an activated heterodimer. The cyclin-CDK complex can phosphorylate 
specific target proteins to coordinate the proceeding into the next cell cycle phase 
•• 
(Vermeulen et aI. 2003). Figure 2.1 shows the simplified regulation of cell eycle 
progression by cyclins and CDKs. 
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Figure 2.1 Regulation of cell cycle progression by cyclins and CDKs. -
Cell cycle can be divided into Go/Gi, S, G2 and M phases and the progression is 
fmely controlled by sophisticated mechanisms. The above simplified figure shows 
the basic regulation by cyclins and cyclin-dependent kinase (CDKs). 
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II. Checkpoints as quality control mechanism 
Induced or spontaneous DNA lesions are common events throughout the life of 
the cells. Chromosomal integrity is preserved by complex surveillance and repair 
pathways. Cell cycle checkpoints are quality control mechanisms to ensure the 
fidelity of cellular processes of the specific cell cycle phase before the progression 
into the next phase. If DNA damage is detected by the sensor mechanisms, 
checkpoints will arrest the cell cycle in order to provide time for DNA repair 
(Lapenna and Giordano 2009). 
At the G|/S checkpoint, DNA damage-induced cell cycle arrest appeared to be 
p53 dependent. Cellular p53 level is rapidly elevated by DNA dama^e’ which in 
turns induces p21, a CDK inhibitor (CKI). Cell cycle progression is paused by the 
inhibition of CDKs to prevent the replication ofdamaged DNA (Ko and Prives 1996; 
Levine 1997). The S phase checkpoint is poorly understood (Vermeulen et al. 2003), 
but some studies demonstrated that both initiation and elongation phases of DNA 
replication were suppressed when DNA damage occurred at this checkpoint 
(Paulovich and Hartwell 1995). G2 checkpoint was proven p53 independent. Entry of 
mitosis is prevented by maintaining CDK1 (also known as cdc2) in its inhibited form 
•• 
by preventing phosphorylation or nuclear extrusion of the CDKl-cyclin B complex 
(Sanchez et al. 1997; Zeng et al. 1998). 
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When cells are being arrested in the checkpoints, attempts will be made to 
repair the DNA damage. If the damage fails to be repaired, the cells will undergo 
self-destruction via apoptosis to prevent cell division with faulty genomic content. 
III. Cell cvcle regulation and cancers 
Cell cycle disruption is a common feature of hyper-proliferative cancer cells. 
Cell cycle regulators including cyclins, cyclin-dependent kinase (CDK), CDK 
inhibitors (CKI), checkpoint proteins and other signal transducers can be deregulated 
by various mechanisms, such as gene translocation, transcriptional activation, 
epigenetic silencing and microRNAs (Malumbres and Barbacid 2007). Cell cycle 
deregulation may result in at least two cancer-associated defects, namely 
unscheduled proliferation and genomic/ chromosomal instability. Genomic instability 
refers to increased DNA mutations and chromosomal aberrations, while 
chromosomal instability involves the change in chromosome number (Malumbres 
and Barbacid 2009). 
Based on the understanding of cell cycle deregulation and cancer, it was 
believed that reinforcement of cell cycle regulation is a feasible strategy for cancer 
•• 
treatment. Extensive researches were done to identify candidate inhibitors that target 
cell cycle regulatory protein to mediate arrest proliferation and induce apoptosis in 
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cancer cells, yet none of them has been approved for commercial use for the time 
being (Lapenna and Giordano 2009). Examples include broad-spectrum CDK 
inhibitors which showed anti-tumor activity in animal models and are now in 
advanced preclinical evaluation (Payton et al. 2006). Cdc25C-associated protein 
kinase 1 inhibitors demonstrated anti-proliferative in cancer cells lacking p53 
expression (Busby et al. 2000). It was also suggested cyclin-binding inhibitors can 
attenuate cell cycle progression by preventing cyclin-CDK complex formation 
(Canela et al. 2006). 
2.1.2 Growth arrest and DNA damage inducible (GADD) genes as cell cycle 
regulators 
I. Discovery 
DNA damage inducible (DDI) genes were first identified as the group of genes 
that the transcript level was increased by stressful conditions such as UV irradiation 
and DNA alkylating agents in Chinese hamster ovary (CHO) cells in 1988 (Fomace 
et al. 1988)，using hybridization subtraction method. The DNA clones were divided 
into two categories. Class I transcripts only showed appreciable induction after UV 
_ 
irradiation, while class II transcripts can be induced by both UV irradiation and 
DNA-base-damaging, for example, alkylating agents. In 1989, the class II DDI 
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transcripts were shown to be associated with growth cessation responses, and thus 
designated as growth arrest and DNA damage inducible (GADD) genes (Fomace et 
al. 1988; Fomace et al. 1989). 
Human GADD genes include GADD34, GADD45A, GADD45B, GADD45G 
and GADD153. Genes and gene products information is briefly described below. 
i. GADD34: The gene is located at 19ql3.2, and is also known as protein 
phosphatase 1，regulatory subunit I5A (PPPlR15A) or myeloid differentiation 
primary response protein 116 (MyD116). It encodes for a protein of 674 amino acids 
in size, which can interact with a diverse array of proteins to moduration cellular 
events including transcription, translation and DNA repair. (Zhan et al. 1994; Grishin 
et al.2001) 
//• GADD45A, GADD45B and GADD45G: The genes encode for three 
evolutionary conserved proteins GADD45 a,p andy of size 165, 160 and 159 
respectively. They are highly homologous, sharing 22-57% overall identity in amino 
acid level and able to interact with each other. GADD45A is located at lp31.2-p31.1 
«• 
and it is also known as DNA damage inducible transcript 1 (DDIT4). lt was 
previously named GADD45 before the other two homologues were found. 
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GADD45B is located at 19pl3.3 and it was known as myeloid differentiation 
primary response protein 118 (MyD118) before identified as DNA damage inducible 
genes. GADD45G from the locus 9q22.1-q22.2 is also known as cytokine response 
gene 6 (CR6) and DNA damage inducible transcript 2 (DDIT2). (Hollander et al. 
1993; Takekawa and Saito 1998; Zhang et al. 1999). 
iii. GADD153: The gene is located at 12ql3.1-ql3.2 and it is also known as DNA 
damage inducible transcript 3 (DDIT3) and C/EBP-homologous protein (CHOP). It 
encodes for a leucine zipper transcription factor of 283 amino acids in size which 
modulates gene expression by directly binding to DNA element or by interacting 
with other transcription factors like AP-1 and members of the C/EBP family 
(Panagopoulos et al. 1996; Ubeda et al. 1999; Wong et al. 2004). 
II. Physiological Role 
Mammalian cells are under persistent challenge of ubiquitous genotoxic agents 
and physiological stress. Such stress-causing agents can be endogenous, generated 
during normal physiological metabolism, or can be exogenous from the myriad of 
«« 
potentially hazardous physical and chemical agents in the environment (Fomacc et al. 
1992). As genome integrity is crucial for the survival of the organisms, cells have 
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their own protective mechanisms to cope with genotoxic stress. The mammalian 
cellular response to stress involves complex processes and one of such mechanism is 
the induction of growth arrest and DNA damage inducible (GADD) genes (Hollander 
et al. 1993). A considerable number of researches were performed to show that 
GADD genes play a role in growth arrest, DNA repair, terminal differentiation and 
apoptosis upon stressful growth conditions. In general, DNA damage or endoplasmic 
reticulum stress causes the induction of GADD genes, and the gene products in tums 
result in growth arrest and enhanced DNA repair to allow time for cellular repair. If 
the damage is irreversible, the cells will undergo apoptosis. The proposed 
mechanisms governed by the GADD proteins as supporting by experimental findings 
are discussed below, although their exact roles were still not fully elucidated (Scott et 
al. 2005). 
i. GADD34: It was believed to have a direct role in the initiation of apoptosis, as 
nuclear fragmentation, a key characteristic of apoptosis, was observed in 
GADD34-transfected cells (Hollander et al. 2001). Upon the association with protein 
phosphatase 1, GADD34 promotes the dephosphorylation of the eukaryotic initiation 
•• 
factor 2 a-subunit (eIF-2a) and alters the gene expression profile (Brush et al. 2003). 
Besides, enhanced hematopoietic cell survival was observed by blocking GADD34 
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expression by antisense oligos in rodents, suggesting GADD34 may play a role in 
terminal differentiation (Liebermann and Hoffman 2002). 
ii. GADD45: It may be involved in the cell cycle regulation, based on the finding 
that transfection of GADD45 caused G2/M phase arrest in cells by inhibiting 
cdc2-cyclin B1 interaction (Wang et al. 1999), As GADD45A was shown to interact 
with proliferating cell nuclear antigen (PCNA), it may play a role in DNA repair by 
enhancing nucleotide excision repair (NER) (Smith et al. 1994). Induction of 
GADD45 was previously believed to be p53 dependent, but recent studies 
demonstrated that the genes can also be induced in p53 deficient cellS (Scott et al. 
2005; Zhan 2005). Besides, the genes are also induced during terminal hematopoietic 
differentiation (Zhang et al. 1999). 
iii. GADD153: It appeared to trigger critical early events of apoptosis initiation, as 
supported by the occurrence of apoptosis after GADD153 transfection in 2001 and 
several subsequent studies (Maytin et al. 2001; Conn et al. 2002; Lengwehasatit and 
Dickson 2002). Besides, microinjection of GADD153 proteins resulted in Gi arrest 
_ 
in NlH-3T3 cells (Barone et al. 1994). 
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The over-expression of each GADD gene alone can cause growth inhibition or 
apoptosis, while the combined over-expression leads to synergistic or cooperative 
anti-proliferative effect, suggesting the GADD genes may inhibit cell growth through 
different and perhaps complementary pathways (Zhan et al. 1994; Hollander et al. 
1997). The induction of GADD genes upon cellular stress is likely to be an active 
and specific response to certain damage rather than a general response to the 
deleterious effect of cell injury, as the response in GADD induction differs among 
damage-inducing agents (Fornace et al. 1992). 
III. Relationship with cancer “ 
Genome instability, for instance incorrect centromere amplification, DNA 
replication and chromosome division, are known causes of tumor development and 
progression (Rosemary Siafakas and Richardson 2009). Cell cycle regulators are 
frequently disabled in cancers, therefore the reinforcement of cell cycle regulation is 
a feasible strategy for cancer treatment (Shapiro and Harper 1999). Moreover, 
abnormality in differentiation response is a distinct characteristic and frequent event 
in many histological dissimilar cancers (Sachs 1978). Differentiation signals trigger 
•• 
successive stages of cell differentiation and growth inhibition. During normal tissue 
turnover terminal differentiated cells will eventually undergo programmed cell death. 
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Therefore agents that can induce terminal differentiation represent a potential 
strategy in cancer therapy (Liebermann and Hoffman 2002; Sarkar et al. 2002). 
Although GADD genes are not hot candidates of mutation in cancers, mutations 
in GADD45A gene are often found in respectable invasive pancreatic ductal 
carcinomas. However, the expression of GADD45A is more commonly reduced in a 
number of cancer types, with promoter methylation in the majority of breast cancers 
resulting in the reduced expression compared with normal breast epithelium (Zerbini 
and Libermann 2005). 
Therefore, any agents that can reinforce the effect of GADD genes in growth 
arrest, terminal differentiation and apoptosis induction would be potential candidates 
for cancer therapy against the unregulated cell proliferation. 
•« 
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2.2 Materials and Methods 
2.2.1 Materials 
2.2.1.1 Cell line 
The human breast adenocarcinoma cell line MCF-7 was purchased from the 
American Type Culture Collection (Baltimore, MD, USA). It was derived from the 
pleural effusion as the site of metastasis of a 69 years old female Caucasian. Some 
characteristics of differentiated mammary epithelium, such as estrogen receptor 
expression, were retained by this cell line. 
2.2.1.2 Cell culture medium, supplements and other reagents 
t* 
I. RPMI 1640medium 
GIBCO® RPMI 1640 medium powder was purchased from Invitrogen Life 
Science. 2.0 g sodium bicarbonate (Na2CO3) was added to each liter of RPMI during 
medium preparation. The pH of the solution was adjusted to 7.2 before being passed 
through a 0.22 i^m membrane filter (Millipore Express® PLUS) for sterilization. 
II. Serum supplement 
GIBCO® Fetal bovine serum (FBS) was purchased from Invitrogen Life Science. 
It was stored at -20 °C as 50 ml aliquots. ‘ 
III. Antibiotics 
GIBCO® Penicillin-Streptomycin-Glutamine (lOOX) (PS) was purchased from 
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Invitrogen Life Science. It contains 10,000 units of penicillin, 10,000 )ig of 
streptomycin, and 29.2 mg of L-glutamine/ml dissolved in 0.85% saline with 10 mM 
citrate buffer to maintain penicillin potency. It was stored at -20。C as 5 ml aliquots. 
IV. Trypsin-EDTA solution 
GIBCO® 0.25% Trypsin-EDTA solution (IX) was purchased from Invitrogen 
Life Science. The solution contains 2.5 g/L trypsin of porcine origin and 0.38 g/L 
EDTA-tetrasodium dissolved in Hanks' balanced salt solution without calcium and 
magnesium. . It was stored at -20。C as 50 ml aliquots. 
V. Phosphate-buffered saline (PBS) 
Phosphate-buffered saline was composed of 136 mM NaCl, 2.7 mM KC1, 
1.5 mM KH2PO4 and 8 mM Na2HPO4. The chemicals were purchased from 
Sigma-Aldrich Co. The solution was adjusted to pH 7.4 and subsequently sterilized 
by autoclaving at 121。C for 20 min. Sterilized PBS was stored at 4。C. 
2.2.1.3 Gene expression assay reagents 
I. RNA isolation 
RNase AWAY was purchased from Molecular BioProducts to remove RNase 




II. Reverse transcription (RT) 
TaqMan® Reverse Transcriptase Reagents was purchased from Applied 
Biosystems. 
III. Polymerase chain reaction (PCR) 
Taq PCRx DNA Polymerase was purchased from Invitrogen Life Science. 
Primers for the amplification of GAPDH, GADD34, GADD45A, GADD45B, 
GADD45G, GADD153 were purchased from Invitrogen Life Science. The primer 
sequences were shown below. 




^ Sense AGGGATGCCCACCCTTTCT 
GADD34 
Antisense ACCAGAGCTGCTCCTTTTACT 
… ^ ^ ^ Sense GAGAGCAGAAGACCGAAAGGA 
GADD45A 
Antisense CACAACACCACGTTATCGGG 
^ , Sense ACAGTGGGGGTGTACGAGTC 
GADD45B 
Antisense ATGAGCGTGAAGTGGATTTGC 
^ ^ … ^ ^^ Sense GTCTACGAGTCAGCCAAAGTC 
GADD45G 
Antisense AAAGCCTGGATCAGCGTAAAAT 




IV. Agarose gel electrophoresis 
UltraPure�M agarose powder (Invitrogen Life Science) and 2 ^1 ethidium 
bromide (Pharmacia Biotech, 10 mg/ml) were dissolved in IX TBE buffer (Genesee 
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Scientific, Apex TBE Buffer containing Tris base, boric acid and EDTA) to constitute 
2% agarose gel. GeneRuler™ 100bp DNA ladder (Fermentas) was used as the DNA 
marker. 6X sample loading buffer was made by dissolving 0.25 % w/v bromophenol 
blue and 40 % w/v sucrose in de-ionized water and stored at - 2 0 � C . 
2.2.1.4 Reagents and buffers for Western blotting 
I. Cell lvsis buffer 
Cell lysis buffer was composed of 2% w/v SDS, 10% v/v glycerol, 625 mM 
Tris-HCl (pH 6.8) and 0.1% v/v aprotinin (protease inhibitor). The chemicals were 
purchased from Sigma-Aldrich Co. Cell lysis buffer was stored at 4 °C" 
II. Bicinchoninic acid (BCA) assay reagents 
Reagent A of the BCA assay was bicinchoninic acid. Reagent B was prepared 
by dissolving CuSO4 • 5H2O at the concentration 4% w/v in de-ionized water. Both 
chemicals were purchased from Sigma-Aldrich Co and stored at room temperature. 
III. Bovine serum albumin (BSA) standard 
Bovine serum albumin (Sigma-Aldrich Co.) standards of 2-10 i^g/^ il was 
prepared by dissolving in de-ionized water. The powder was stored at 4。C while the 
•• 
standard solutions were stored at -20 °C • 
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IV. N,N,N\N'-Tetra-methvlethvlenediamine (TEMED) 
TEMED was purchased from Bio-Rad and was stored at 4。C in light-exclusive 
container. 
V. Ammonium persulfate (APS) 
Ammonium persulfate was purchased from Bio-Rad. 10% w/v working solution 
(10%, w/v) was prepared by dissolving 0.1 g APS powder in 1 ml de-ionized water 
and stored at -20�C. 
VI. Acrvlamide/ bis solution (30%, w/v) 
N,N'-methylene-bis-acrylamide electrophoresis purity reagent (37.5:1) was 
purchased from Bio-Rad and stored at 4 � C . The 500 ml ready-to-us^ solution was 
composed of 146.1 g acrylamide and 3.9 g N,N'-methylene-bis-acrylamide at a total 
monomer to cross-linker ratio of 37.5:1. 
VII. Sample loading buffer 
2X Sample loading buffer was composed of 0.2% w/v bromophenol blue, 4% 
w/v SDS, 20% v/v glycerol, 5% v/v P-mercaptoethanol and 100 mM Tris-HCl (pH 
6.8). The chemicals were purchased from Sigma-Aldrich Co. Loading buffer was 
stored at 4 � C . 
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VIII. Protein standards 
High range molecular weight protein marker RPN756E was purchased from 
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Amersham Biosciences. 
IX. SDS running buffer 
10X SDS running buffer was prepared by dissolving 30.3 g Tris-base, 144 g 
glycine and 10 g SDS in 1L of de-ionized water. 
X. Transfer Buffer (E-blot buffer) 
10X Tris-glycine (pH 8.0) was prepared by dissolving 33 g Tris-base and 144 g 
glycine in lL of de-ionized water. E-blot buffer was constituted by 66.7 ml 10X 
Tris-glycine, 100 ml methanol (Scharlau) and 500 ml de-ionized water. 
XI. Polvvinvlidene fluoride (PVDF) membrane 
PVDF membrane with pore size of 0.45 i^m was purchased from Millipore 
Corporation. 
XII. Phosphate-buffered saline-Tween (PBST) washing buffer 
PBST was prepared by adding 1% v/v Tween® 20 (USB Corporation) to IX 
phosphate-buffered saline. The solution was stored at 4 °C. 
XIII. Blocking solution- 10% Non-fat milk solution 
Blocking solution was freshly prepared by dissolving non-fat milk powder 
(Nestle) in PBST at the concentration 10% w/v. 
•“ 
XVI. Antibodies -
i. Primary antibodies 
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Mouse monoclonal anti_p_actin antibody was purchased from Sigma-Aldrich 
Co. Mouse monoclonal anti-cyclin A, B1 and E antibodies were purchased from Cell 
Signaling Technology. Rabbit polyclonal antibody to cyclin D1 was purchased from 
Abcam. All primary antibodies were stored at -20 °C. 
ii. Secondary anti-bodies 
Horseradish peroxidase (HRP)-conjugated goat anti-mouse immunoglobulin G 
(IgG) and HRP-conjugated mouse anti-rabbit IgG secondary antibodies were 
purchased from Zymed. The antibodies were stored at 4 � C . 
XV. Western blotting detection reagents and films 
The enhanced chemiluminescence (ECL) reagents were purch"ased from GE 
Healthcare and stored at 4 °C. 
Medical X-ray films were purchased from Fujifilm Corporation. They were kept 
at room temperature in dark. 
2.2.1.5. Cell cycle analysis reagents 
I. 70% Ethanol 
70% v/v ethanol was prepared by diluting absolute ethanol (Scharlau) with 
•• 
de-ionized water in 7:3 ratio. -
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II. Propidium iodide (PI) 
2 mg/ml propidium iodide was prepared by dissolving PI powder 
(Sigma-Aldrich Co) in de-ionized water and stored at 4。C under subdued light. 
III. Ribonuclease A (RNase A) 
10 mg/ml Ribonuclease A solution was prepared by dissolving RNase A of 
bovine pancreas origin (Sigma-Aldrich Co) in de-ionized water and stored at - 2 0 � C , 
2.2.2 Methods “ 
2.2.2.1 Cell line propagation and subculture 
MCF-7 cell line was maintained in RPMI 1640 medium supplemented with 10% 
fetal bovine serum (FBS) and 1% v/v antibiotics (PS). The cell line was cultured in 
75 or 150 cm^ tissue culture flask (IWAKI) and incubated at a 37。C humidified 
incubator with 5% CO2 supplied. 
For subculture, the medium was discarded and the adherent cells were rinsed 
with pre-warmed PBS. 1.5 ml (for 75 cm^ culture flask) or 3 ml (for 150 cm" culture 
•• 
flask) trypsin-EDTA solution was added and incubated at 37。C for 2 min. Complete 
RPMI medium was added to cease trypsinization. 
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2.2.2.2 Whole-transcript expression microarray analysis 
2 X 10^  MCF-7 cells were seeded onto each well of a 6-well culture plate 
(IWAKI) for 24 h to allow adhesion. After Pa-PDT, the cells were further incubated 
for 24 h，which is a common post-irradiation incubation duration practiced in PDT 
assays. Then the cells were harvested by trypsinization and RNA was extracted by 
the RNA NucleoSpin® RNA II Total RNA Isolation kit according to the user manual. 
RNA samples were subjected to whole-transcript expression microarray analysis 
by Affymetrix. The expression array used was The GeneChip® Human Gene 1.0 ST 
Array, which contained whole-transcript coverage. In contrast to classical 3'-based 
expression array design, each of the 28,869 well-annotated genes was represented by 
approximately 26 probes spreading across the full length of the gene in the 
GeneChip® Human Gene 1.0 ST Array. It assured a more complete and accurate 
picture to be presented by eliminating the influences of alternative splicing, 
nonpolyadenylated mRNA, truncated transcripts and genomic deletions. 
2.2.2.3 GADD genes expression assay- RT-PCR 
I. RNA isolation 
3 X 106 MCF-7 cells were seeded on a 100 mm culture dish (IWAKI) for 24 h to 
•• 
allow adhesion. 24 h after Pa-PDT treatment, cells were harvested by trypsinization 
and RNA was extracted by the RNA NucleoSpin® RNA II Total RNA Isolation kit 
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according to the user manual. 
II. RNA Quantification 
RNA concentration was determined by measuring the absorbance at 260 nm 
(A260) by spectrophotometer (Eppendorf), The A2e0/ A280 ratio ranged from 1.8 to 2.4. 
The RNA was stored at -80C for not longer than a month. 
III. Reverse transcriptase- polymerase chain reaction (RT-PCR) 
Semi-quantitative analysis of the mRNA levels of the GADD34, GADD45A, 
GADD45B, GADD45G, GADD153, and the housekeeping gene GAPDH was 
carried out by RT-PCR with the number of cycles at which the band intensity 
increased linearly with the amount of mRNA present. “ 
500ng of total RNA was reversely transcribed to complementary DNA (cDNA) 
prior to the amplification of target genes by PCR. The reagents per reaction were as 
indicated below: 
Volume (^il) 
10x Reaction Buffer 5 
MgCl2(25 mM) 11 “ 
dNTP(lQmM) 10 
Random Hexamer (50 ng/ i^l) 1.25 
Oligo d(T)i6 (50 ^iM) 1.25 
RNase Inhibitor (20 U/ i^l) 1 ‘ 





The program of the thermo-cycler (GeneAmp® PCR System 9700，Applied 
Biosystems) was shown in the following figure. 
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cDNA samples obtained were stored at -20 °C before the amplification of the 
targeted genes, GADD genes and GAPDH by PCR. The reagents per PCR were as 
indicated as follows. 
t 
Volume (^il) 
10x Reaction Buffer(-MgCl2) 2 
MgCl2 (50 mM) 0.6 
dNTP (2.5 mM) 1.6 
Taq DNA polymerase (5 U/|il) 0.1 
dH2O 12.7 
cDNA sample 2 
Primer Mix (Forward+ Reverse) 1 
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The PCR products were resolved by gel electrophoresis. 2% agarose gel was 
pre-stained with ethidium bromide and visualized by a ultra-violet light cabinet 
(Alpha Innotech Corporation). 
2.2.2.4 Cell cycle analysis 
t* 
5 X 10^  MCF-7 cells were seeded onto each well of a 6-well culture plate 
(IWAKI) for 24 h to allow adhesion. At different time point (4，16, 24, 48’ 72 h) after 
Pa-PDT treatment, cells were harvested by trypsinization and washed once with PBS. 
Then the cells were fixed with 1 ml 70% ethanol ovemight at 4 °C • After fixation, the 
samples were centrifuged at 720 x g for 10 minutes, supernatant was removed and 
the cell pellet was washed in PBS once. Then the cell pellet was resuspended in 0.5 
ml freshly prepared propidium iodide (PI) staining solution containing 10 |_il PI (2 
mg/ml)，50 i^l RNase A (10 mg/ml) and 440 i^l PBS. The samples were incubated at 
37 °C under subdued light. After staining, the cells were analyzed by the FACSCanto 
flow cytometer (BD Biosciences) with and the software ModFit LT 3.0. 
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2.2.2.5 Western Blotting 
I. Protein extraction 
3 X 10^  MCF-7 cells were seeded on a 100 mm culture dish (IWAKI) for 24 h to 
allow adhesion. 24 h after Pa-PDT treatment, cells were harvested by trypsinization 
and washed twice with PBS. The cell pellets were lysed by 100 i^l cell lysis buffer 
and heated in boiling water bath for 10 min. The lysates were then vortexed 
vigorously and centrifuged at 20,000 x g for 15 minutes at 4 °C. The supematants 
were transferred to a new microfuge-tube and stored at -20 °C. 
II. Determination of protein concentration 
The concentration of protein samples was determined by bicinchoninic acid 
(BCA) assay. Reacting mixture was freshly prepared by mixing reagent A (BCA) 
with reagent B ( 4% w/v CuSO4 • SHzO) in 49:1 ratio. 200 i^l reaction mixture and 3 
U^ protein sample or BSA standards or lysis buffer (as blank) were added to each well 
o f a 96 well plate in duplicate. After 30 min incubation at 37 °C，the absorbance at 
540 nm was measured by a microplate reader (Bio-Rad). Protein concentration ofthe 
samples was calculated with reference to the BSA standard curve. 
III. SDS-Polvacrvlamide gel electrophoresis (SDS-PAGE) 
«• 
Proteins in the sample were resolved according to their molecular weight in 
SDS-PAGE. The polyacrylamide gel consisted of two parts, the upper stacking gel 
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and the lower separating gel. The constituents of the gel were shown bwlow. 
Stacking Gel Separating Gel 
(5%, 3ml) (12.5%,5ml) 
Acrylamide solution (30%) 0.5 ml 2.08 ml 
Upper Gel Buffer 
(0.5 M Tris, pH 6.8， 0.75 ml — 
0.4% w/v SDS) 
Lower Gel Buffer 
(1.5MTris, pH 8.8, 一 1.25 ml 
0.2% w/v SDS) 
De-ionized water 1.707 ml 1.593 ml 
10%APS 4 ^ 75 i^l 
TEMED 3fil 2|^il — 
M 
When SDS-PAGE was completed, the stacking gel was discarded while the 
separating gel was rinsed with transfer (E-blot) buffer. 
IV. Semi-drv transfer of protein to PVDF membrane 
A piece ofPolyvinylidene fluoride (PVDF) membrane was pre-wetted by 100% 
methanol then equilibrated in E-blot buffer. Two pieces of filter paper soaked with 
E-blot buffer were placed onto the Trans-blot® Semi-dry Transfer Cell (Bio-Rad), 
with the PVDF membrane on top of it. The separating gel was placed on top of the 
PVDF membrane and two pieces of filter paper soaked with E-blot buffer were 
placed on top of the gel. A constant current of 0.15 A was applied for 30 minutes for 
electroblotting. 
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V. Enhanced chemiluminescence (ECL) detection 
After electroblotting, the PVDF membrane was blocked with 10% non-fat milk 
solution for 30 min in a centrifuge tube mounted on a rotator. The membrane was 
subsequently probed with primary antibody against the target protein by adding the 
manufacturer-suggested dilution ratio of antibody to 10% non-fat milk overnight at 4 
°C. Then the membrane was washed with PBST for 3 times, 5 min each before 
probing with the corresponding horseradish peroxidase-linked secondary antibody 
for 1 h. After incubation, the membrane was washed with PBST for 3 times, 5 min 
each. 
»* 
The membrane was equilibrated with the freshly mixed luminol reagents (0.5 ml 
each) for 1 min. Luminescence was produced proportional to the amount of protein 
present. A X-ray film was placed on top of the membrane to create an image inside a 
dark room. The film was developed and fixed by a X-ray film processor (Kodak). 
2.2.2.6 Statistical analysis 
Experimental results showed were the representative data of at least 3 
independent experiments with consistent results. Data were expressed as means 士 
standard deviation (SD). The difference between groups was assessed by one way 
«• 




2.3.1 Effect of Pa-PDT on GADD genes expression by whole-transcript 
expression microarray analysis 
In order to better understand the anti-proliferative mechanism of Pa-PDT on 
MCF-7 cells, mRNA microarray analysis was performed. MCF-7 cells were treated 
with Pa-PDT at a dose equivalent to the IC50 value (0.5 ^iM). 24 h afterwards, total 
RNA was isolated and whole-transcript expression microarray analysis was carried 
out by Affymetrix (The GeneChip® Human Gene 1.0 STArray). 
The change in expression of level of several GADD genes, which are cell cycle 
»* 
regulators, was picked out for further investigation. The expression of GADD34, 
GADD45A, GADD45B, GADD45G and GADD153 were generally increased after 










Table 2.1 Change in GADD genes mRNA expression level in MCF-7 cells after 
Pa-PDT. 
Total RNA was isolated from MCF-7 cells 24 h after treatment with 0.5 ^M Pa-PDT 
and subjected to whole-transcript expression microarray analysis by Afifymetrix (The 
GeneChip® Human Gene 1.0 ST Array). The expression level of GADD34, 
GADD45A, GADD45B, GADD45G and GADD153 was expressed"as the fold of 




2.3.2 Effect of Pa-PDT on GADD genes expression by RT-PCR 
The induction of GADD genes by Pa-PDT in MCF-7 cells was confirmed by 
reverse transcriptase-polymerase chain reaction (RT-PCR). MCF-7 cells were treated 
Pa-PDT and 24 h afterwards, total RNA was isolated and RT-PCR was carried out to 
determine the mRNA expression of GADD34, GADD45A, GADD45B, GADD45G 
and GADD153. 
MCF-7 cells were treated with 0-0.45 i^M Pa-PDT and the result was shown in 
Figure 2.2. The mRNA levels of GADD34, GADD45A, and GADD45G were 
increased by Pa-PDT in a dose-dependent manner. GADD153 mRNA level was 
elevated by Pa-PDT, but the induction was similar for all three doses of Pa-PDT. The 
mRNA level ofGADD45B was not affected by Pa-PDT. 
• • 
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O^M 0.15nM 0.3 ^M 0.45 ^M Pa-PDT 
GADD34 • ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
— — M 
GADD45B • ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
— I ^ ^ Q Q I 
GADD153 • j ^ J j j ^ H ^ ^ J J p j j | ^ ^ J ^ J J J 
— • i m u i ^ j j m ^ j j j ^ u j j j i 
Figure 2.2 mRNA expression of GADD genes in MCF-7 cells after Pa-PDT. 
MCF-7 cells were treated with Pa-PDT of 0.15，0.3 and 0.45 ^iM. mRNA was 
isolated 24 h afterwards and reverse transcribed into cDNA. cDNA was amplified 
and the PCR product was separated by 2% agarose gel pre-stained with ethidium 
bromide. Gel photos shown are representative results of 3 independent experiments 
with consistent trends. 
«• 
4 7 
2.3.3 Temporal change in the cell cycle profile after Pa-PDT 
MCF-7 cells were treated with 0-1 i^M Pa-PDT and fixed at indicated 
time-points (4-72 h). Dark controls referred to MCF-7 cell treated with Pa only, 
without irradiation and time-points of 24, 48 and 72 h were included. 
Cell cycle profiles were shown in Figure 2.3. In Figure (A) to (C), the dark 
controls indicated that Pa did not cause any significant change in cell cycle 
distribution up to 72 h. 
No significant change in cell cycle profiles was observed at 4 h and 16 h after 
Pa-PDT. 24 h after Pa-PDT, a statistically significant decrease in Go/G| population 
$* 
was detected at 0.8 and 1 i^M of Pa-PDT while an increase in G2/M population was 
observed at 0.6’ 0.8 and 1 i^M Pa-PDT without significant change in S phase, 
demonstrating a G2/M arrest. 48 h post-Pa-PDT, Go/G! population was reduced 
significantly for all doses of Pa-PDT, while G2/M population was increased by 0.4， 
0.6 and 0.8 i^M Pa-PDT with no significant change in S phase, implying a G2/M 
arrest. Sub-Gi peak corresponding to sub-diploid DNA content was observed in 
1 i^M Pa-PDT, indicating the occurrence of DNA fragmentation. 72 h after Pa-PDT, 
• • 
the sub-Gi population increased with Pa-PDT in a dose-dependent manner. 
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(A) 24 h Dark control 
0 i^M Pa 0.2 \iM Pa 
Go/G,: 55.46% , Go/Gi： 52.79% 
IG 2 / M : 9.63% ： G 2 / M : 11.81% 
S:34.91% s^ I S: 35.87% d • DlpG1^ - • •CMpGI • Dip G2 . • • Dp G2 El Dlp S • H Dip S 
^ ^ f ^ i , , i � � i ^ # ? ^ ^ f ? ^ i i i i i u 川 卯 ^^  60 80 100 120 20 4 0 60 80 100 120 
Channels (PE-A) Channete (PE-A) 
t* 
0.4 i^M Pa 0.6 i^M Pa 
: Go/G,: 54.54% ： Go/G,: 53.68% 
|j 1 G 2 / M : 10.6% ^ I G 2 / M : 10.77% 
"： I S : 3 4 . 8 7 % "： I S : 3 5 . 5 6 % 
J： 里 §^  I 
I: I }； I 
‘ I i i , r I - i r 
‘ I ^ I 
� | T ， ％ ^ ^ ^ ^ : 4 , _ i r , j P w ^ ? ^ ^ # h ^ 
G h a _ M P E - A ) “ » ^° Channe^(PE-A) ‘ “ ^ “ ‘ ^ ^ 
«« 
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0.8 ^M Pa 1 \iM Pa 
Go/Gi: 5 2 . 5 2 % Go/G, : 5 5 . 2 5 % 
H G2/M : 9.87% 8： j G2/M : 10.14% 
I S : 3 7 . 6 1 % I S : 3 4 . 6 1 % 
i^ I i . I 
• • DipG1 H • Di'jCI • • Dip G2 _ • DID G2 � “ • C3 Dlp S H E LM3 S 
• ^ • 
。： i ^ W f ^ ^ v ^ � j ^ F F ^ ¥ ^ W n 
0 20 40 � 60 60 100 120 20 40 eO 80 ^00 120 
Channels (PE-A) Chamtle (PE-A) 
H 
Pa conc ( i^M) Gp/Gi Phase (%) G2/M Phase (%) S Phase (%) 
0 53 .39 土 2 .53 11.07 土 1 . 5 T ~ 3 5 . 5 4 土 0 . 97 
0 . 2 5 1 . 9 9 土 3 . 3 8 1 2 . 6 5 土 1 . 1 0 3 5 . 3 7 士 2 . 4 8 
0.4 53 .58 ± 2 . 4 1 1 1 . 6 0 ± 1.41 3 4 . 8 2 士 1 . 1 5 
0 .6 5 3 . 2 9 土 3 .18 U . 8 9 i l . l 8 3 4 . 8 2 土 2 .57 
0.8 52.38 土3.78 1 1 . 1 5 ± l i ^ 36.48 ±3.42 
1 5 4 . 2 6 土 4 . 0 5 1 1 . 0 5 士 1 . 4 7 3 4 . 6 9 土 2 . 7 2 
• • 
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(B) 48 h Dark control 
0 i^M Pa 0.2 ^M Pa 
^ 1 Go/Gi： 6 3 . 2 7 % G o / G , : 6 6 . 3 1 % 
I： G2/M : 10.22% ^ I G2/M: 9.29% 
： S : 2 6 . 5 1 % 。： I S :24 .40o/o 
0 o— • 
iT ° . I 
p I d I 
§- • • Uipb- ？- • • Dip G1 • • MPG2 • • DipG2 • S ap s • E3 Dip E 
^ M • ^ M 
� 1 • , . • f ^ r r i ^ ' f r " ^ • , , , , . , , . , ^^竹’沖广：'、^^. • • • i 
“ 、 二 、 - 八 ) 8 。 1 〕 。 丨 " ° - ^cLj^(PE-A, 1 " 1=» 
«4 
0.4 nM Pa 0.6 \iM Pa 
G o / G , : 6 3 . 8 6 % G o / G , : 6 5 . 4 0 % 
^ G2 /M : 11.130/0 ^ G2 /M : 1 0 . 6 0 % 
I S : 2 5 . 0 1 % S: 2 4 . 0 0 % 
- I ^ 
i^ I t I 
m • D i p G i • • ni'r r.i m • Dp G2 • • Dip G2 0 . ffi t^ Dp S � • • S D^  S 
- • • I / ^ t t Y Y Y T t ^ { % r r ^ ^ c^  . • • • I • • • • , 攀 1 ^ 、 \ 印 秦 . , , I 
� “ ^ “ Chonn^ s"(PE-A) «° ™^ ^^ “ ^ ^ CI....^ (^PE-A) °^ '^ “ � 
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0.8 nM Pa 1 ^M Pa 
Go/G, : 6 6 . 8 9 % Go/Gi： 6 5 . 0 5 % 
§ � G 2 / M : 9 . 7 i % ^ I G 2 / M : 8 . 9 4 % 
S : 2 3 . 4 1 % S : 2 6 . 0 1 % 
- I ^ 
1 . I t 
ffl • Dlp G1 . i • CipG1 
flH “ Dip G2 • 1 • CipG2 
• fc^DifS I t^CipS 
/徵|、、、、、、,,秦,,,|o： : 驟恍、，、>^^^^^^^ 
� 2» .0 c:hamJf^ PE_A> [ � '"" 叨^ ？• <�ol:(PE-A> ™ ^ ^^ 
t* 
Pa conc (^ iM) Gp/Gi Phase (%) G2/M Phase (%) S Phase (%) 
0 6 5 . 2 7 土 2 .75 9 .92 土 l . Q ^ 24 .81 土 1.84 
0 . 2 6 6 . 6 2 土 0 . 8 1 9 . 3 3 土 0 . 4 5 ~ 2 4 . 0 5 士 1 . 2 0 
0 .4 6 6 . 3 9 土 3 . 17 9 .75 土 1 . 5 ^ ~ 2 3 . 8 6 土 1.70 
0 .6 6 7 . 5 9 土 2 .11 9 .33 土 l . l 7 ~ 2 3 . 0 8 土 0 . 9 6 
0 . 8 6 6 . 9 4 土 2 . 4 6 9 . 1 9 土 0 . 6 ^ " " 2 3 . 8 8 土 2 . 1 0 
1 6 6 . 1 7 土 2 . 74 8 .38 土 1.07 2 5 . 1 4 士 1 .40 
«« 
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(C) 72 h Dark control 
0.2 ^M Pa 
i Go/G, : 7 0 . 4 0 % 
I- I I： I G 2/M : 10.60% 
1 � I S: 18.99% 
^ 1 ^ I 
|H[ • Ulf U1 翻 • Dip G1 ^ n • D(|: Q2 _ • Dip G2 
I： • ^D(pS 1^ H f^DipS 
- • • •, I. • 1111HB11 ‘ 1111 � 轉 11.1 ^Wn�?^%W| 
‘ '0 ^ C h « n J s V [ - A ) B 。 、撒 1冬。° 20 ^° Chann^s°(PE-A) ^° ' ^ ' ' ' 
H 
0.4 i^M Pa 0.6 i^M Pa 
G o / G , : 6 7 . 5 7 % Go/G, : 6 7 . 4 9 % 
1G2/M : 11.50% ： G 2/M : 10.58% 
S： 2 0 . 9 2 % 1： i S : 2 1 . 9 3 % 
§- 墨 
|i- • I • DlpGI HH • OipG1 P|DlpG2 n ^ • Dip G2 
^ B °"'' 
, , , „ J ? ^ F ^ ^ ^ f i i ^ ^ h . I � � . i i , i i . , • , , ^ m f n ^ ^ 
““Ch3rnc^^(PEA)" ^^ ' ^ ° 20 ^ Cha^PE-A, - " - ^ -
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0.8 nM Pa 1.0 nM Pa 
§ J G o / G , : 6 6 . 7 6 % o J G o / G , : 6 7 . 6 4 % 
‘ : 1 Gs/M : 11.63% ° ： I G2/M : 11.40% 
^ I S : 2 1 . 6 2 % g^ I S : 2 0 . 9 6 % 
I I 
威 匿 ‘ • 
里 I 
^ H §~ • 
^ 1 B 〕 I n B 
� i , ， ， f e ^ l ‘ ， , , , , r l ^ ^ ^ # S 
i^namas .K_ •〜 Channels (PE-A) 
H 
Pa conc (^M) Go/G! Phase (%) G2/M Phase (%) S Phase (%) 
0 6 7 . 9 3 士1 . 4 8 1 2 . 1 4 d : l . l l 1 9 . 9 3士 1 . 3 4 
0 . 2 6 8 . 6 4士 2 . 2 0 1 1 . 7 4士 2 . 1 5 1 9 . 6 2士 1 . 6 3 
0 . 4 6 8 . 2 1 士 3 . 1 9 1 1 . 3 8 土 2 . 4 3 2 0 . 4 1 ± 1 . 7 6 
0 . 6 6 6 . 5 1 土 1 . 8 3 1 2 . 4 8 士 1 . 7 1 2 1 . 0 1 土 2 . 2 9 
0 . 8 6 6 . 3 6士 0 . 7 1 12 .07士 1 .28 2 1 . 5 7士 1 . 6 1 
1 6 6 . 9 7士 2 . 3 2 1 1 . 6 9 土 1 . 8 ^ ~ ~ 2 1 . 3 3 ± O j g _ 
• • 
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(D) 4h after Pa-PDT 
0 nM Pa-PDT 0.2 ^M Pa-PDT 
Go/Gi： 6 5 . 6 3 % G o / G , : 6 3 . 3 3 % 
； G2/M : 11 .25% � ： G2/M : 12 .56% 
胃— I S : 2 3 . 1 2 % ^ I S : 2 4 . 1 1 % 
I 一 I 
里 •€ I 
H • DlpG1 H • D'P G1 
| J • g ^ S f ^ • 匪認『 
。」 ^ m 7 f W ^ y , ^ - 最 — ； ^ \ > < ^ 1 , , , 
20 ^0 channe^(PE-A, ^° ^ ° ' 2 0 〕 » ^° 3hanno^(PEA, ^ ^ » [巧 
t* 
0.4 i^M Pa-PDT 0.6 i^M Pa-PDT 
G o / G , : 6 4 . 3 1 % Go/G, : 6 3 . 4 2 % 
8： G 2 / M : 10.54% ： i G 2/M : 10.70% 
I S : 2 5 . 1 5 % I S: 2 5 . 8 8 % 
I 1 丨 I 
o- H • DipGl • • 3iMGl ^ - • ( • Dip G2 ^ B • Dip G2 
| H | Q Dip S ^ ^ ^ 0 )ip 
� � | , , | | i , , i | ^ ^ f ^ ^ ^ - l i w w t f ^ s . , , 
0 20 40 皿 60 80 1^00 120 ° 0^ 40 ^ . , fO 60 ，00 1S0 
Channels (PE-A) Chamds (PE-A) -
55 
0.8 \iM Pa-PDT 1 i^M Pa-PDT 
Go/G, : 6 5 . 4 0 % Go/G, : 6 2 . 2 2 % 
。•！ G2/M : 10.41% Gi/M : 11.16% 
o— • 
①： I S : 2 4 . 1 9 % 。： S: 2 6 . 6 2 % 
I S『 • 
I 1^  • 
H • DipG1 ^ ^ H • 0(pG1 gJ ^H • Dip G2 n B • Ulp LTJ � . ^ ^ E] DipS 1 ^ ^ S DipS 
� - ‘ I ‘ • I • ‘ I ‘ I I ^ ^^^Y7^fV^l^^^^^^V]o 1 I I I [ I T - T - T - [ ^ B ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
° 20 40c_4。(pE—A)8。 ^0t ,20 0 Jo 4、Li、PE-A)‘ 二 ^^ 
ff 
Pa conc ( i^M) Gp/Gi Phase (%) G!/M Phase (%) S Phase (%) 
0 6 6 . 1 8 土 1.49 11.44 土 0 . 6 9 2 2 . 3 9 士 2 .11 
0 . 2 6 5 . 8 3 土 2 . 3 8 " . 5 9 士 1 . 1 3 2 2 . 5 8 土 1 . 9 3 
0 . 4 6 5 . 4 3 土 2 . 3 7 1 1 . 0 3 土 1 . 5 8 2 3 . 5 4 土 1 . 8 8 
0 . 6 6 2 . 4 1 土 1 . 5 6 " . 5 9 士 1 . 5 7 2 6 . 0 0 土 0 . 7 3 
0 . 8 6 5 . 0 0 土 2 . 0 7 1 0 . 8 1 土 1 . 5 8 2 4 . 5 2 土 1 . 5 1 
1 6 3 . 1 9 土 3 . 1 9 1 0 . 5 3 土 0 . 5 2 2 6 . 2 9 士 2 . 7 1 
_ 
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(E) 16 h after Pa-PDT 
0 nM Pa-PDT 0.2 i^M Pa-PDT 
Go/Gi : 6 4 . 8 1 % Go/G, : 6 8 . 1 6 % 
i G2/M : i2.O6% i G2/M: 11.51% 
^ 1 S : 2 3 . 1 3 % I： I S: 2 0 . 3 4 % 
纽 ^ ^1 
o- ^1 ^1 
丨 ） I '^  1 
9H • D(p C1 ^ H • OipGl 
^ H “ ot T o j | H ^ B "ps^  
j ^ ^ ^ ^ w ^ ^ ^ j s ， 。 : J l ^ , l - h f ^ ^ ^ , , I 
0 30 / 0 60 80 ^ 0 0 123 0 20 40 60 80 " o 120 
Channels (PE-A) Channels (PE-A) 
n 
0.4 nM Pa-PDT 0.6 \xM Pa-PDT 
Go/G, : 6 9 . 9 8 % Go/G, : 7 2 . 0 0 % 
IG2 /M : 10 .83% g J I G2 /M : 1 0 . 8 5 % 
S: 19 .19% ° ' I S: 1 7 . 1 6 % 
I 
•��PG1 ^ H • D G1 
s s s � 8 ： • g s i r 
. . - . N l ^ # ^ n L ^ r ^ H ^ ^ ^ N ^ 
Channels(PE-A) ° ^° ^° Chann4°(PE-A) ^° ^ ° ° ^^° 
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0.8 ^M Pa-PDT 1 ^M Pa-PDT 
Go/G,: 7 1 . 0 0 % Go/Gi: 71.11% 
1G2/M : 11 .65% I： i G 2 / M : 12 .03% 
S: 17 .35% 1 S: 16 .86% 
^ 1 
1 • DipG1 ^ ^ ^ • Dip G1 1 • Dip G2 _ . ^ H l • D'P G2 
fc 0 D(p s ° - ^ m E3 Dip S 
^ W ^ ? ? ^ ^ ^ ¥ > I I f ^~ I I ‘ I I I I ‘ r | ^ f f % ? ? ^ ^ ^ ^ r T T ~ n 
^u Al ffi BO ^ 100 13o0 20 40 60 80 100 120 
Channels (PE-A) Channels (PE-A) 
t* 
Pa conc (^M) ^ G i Phase (%)|G2/M Phase (%) S Phase (%) 
0 6 7 . 3 3 士 5 . 3 2 1 3 . 9 6 士 1 . 6 9 1 8 . 7 1 士 3 . 8 7 
0 . 2 6 7 . 7 9 ± 2 . 7 8 1 1 . 9 8 士 0 . 4 1 2 0 . 2 3 士 1 . 2 7 
0 . 4 6 6 . 8 5 士 2 . 9 2 1 0 . 7 7 土 0 . 2 7 2 2 . 3 8 士 2 . 8 9 
0 . 6 6 8 . 6 8 士 2 . 9 6 1 0 . 9 3 士 2 . 0 1 2 0 . 4 0 士 3 . 0 8 
0 . 8 6 6 . 3 0 士 4 . 2 1 1 2 . 1 4 士 1 . 4 2 2 1 . 5 6 士 3 . 6 6 
1 6 8 . 5 9 土 5 . 9 6 1 0 . 9 8 士 1 . 9 0 2 0 . 4 3 士 3 . 5 7 
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(F) 24 h after Pa-PDT 
0 ^M Pa-PDT 0.2 \iM Pa-PDT 
- . Go/Gi： 6 2 . 5 5 % G o / G i : 6 3 . 1 6 % 
I G 2 / M : 11.67% I G 2 / M : 12.10% 
碧： I S: 25.78% 。： I S: 2 4 . 7 4 % 
I “ I 
§- 9 • fH ^H Q> • ^M 
昔 . n ^o' • 
I ： I r I 
o__ IH ^ ^ 
^- • • DIP G1 : • • DlpG1 
LB Dip G2 • • D[pG2 El Dip S ^ H | S Dips 
A flk^^^ 
r � Y � \ ， \ Y ， j ^ p ^ . 丨 , . 一 , , I , I , r ^ ^ ^ | w w w ^ | • • • 
30 60 90 120 30 屣60 90 1 ¾ 
Channels (PE-A) Channete {PE-A) 
M 
0.4 nM Pa-PDT 0.6 i^M Pa-PDT 
1Go/G,:61.34% Go/G,:60.51% 
G2 /M : 13 .87% j | G2 /M : 14 .09% 
S： 2 4 . 7 9 % ^ I S: 2 5 . 4 0 % 
I =^^ : • s-p-
• u i p ^ • B s s r 
^ ^ b ^ : | ^ S ^ ^ ^ _ . .. 
见 60 90 • ^lo ‘ ‘ I ‘ I ‘ ‘ ^ T ' ' ‘ ‘ n ^ I ' • ‘ .^ hannels(PF-A) ‘‘ 30 60 90 巢 lk) 
‘ Channels (PE-A) -
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0.8 nM Pa-PDT 1 ^M Pa-PDT 
C G o / G , : 5 8 . 9 8 % 
。： H G2 /M : 1 5 . 4 4 % 
^ i S: 25.58% 
c I DipG1 ^ B • DipC1 
Dip G2 „ . ^ H • Dip G2 
Dip S 1 ^ ^ n H Dlp S � J ^ ^ | l , l 
__ � 30 60 30 1?0 
Channels (PE-A) Channels (Pb-A) 
u 
Pa conc (nM) Gp/Gi Phase (%) G2/M Phase (%) S Phase (%) 
0 6 5 . 7 9 士 2 . 3 7 9 . 7 0 士 1 . 4 6 2 4 . 5 1 士 1 . 1 2 
0 . 2 6 4 . 2 8 士 2 . 1 2 1 1 . 2 3 士 0 . 6 7 2 4 . 4 9 土 1 , 7 0 
0 . 4 6 3 . 0 5 士 2 . 6 7 1 0 . 9 5 士 2 . 0 1 2 6 . 0 0 士 2 . 7 8 
0 . 6 6 2 . 4 0 士 3 . 1 5 1 2 . 5 0 ± 1 . 6 9 * 2 4 . 4 4 士 1 . 5 4 
0 . 8 6 0 . 0 2 士 3 . 2 4 * 1 3 . 7 1 土 1 . 1 4 " 2 6 . 2 7 士 2 . 4 5 
1 5 8 . 5 8 士 3 . 4 8 * * 1 4 . 7 8 士 0 . 4 4 * * * 2 6 . 6 4 士 3 . 5 1 ~ ~ 
«• 
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(G) 48 h after Pa-PDT 
0 nM Pa-PDT 0.2 i^M Pa-PDT 
Go/G,: 64.03% Go/G,: 56.66% 
G 2 / M : 13.11% gj C G 2 / M : 13.98% 
§- I S: 2 2 . 8 6 % " ： I S: 29.36% 
1 ' I • i ； I 
• • DipG1 • • OipGl 
。 . • • DipG2 • • Oip G2 
§ - H E 3 D ips ^ 1 S D ips 
‘ i ^ r ? ? T W ^ i •. p^  . . , , , . •. • ^ f f # f ^ w ^ 
2� 4 � c h ^ 4 V E _ V � � � 劃 20 -cL^PE-A)80 • I � � 120 
n 
0.4 nM Pa-PDT 0.6 ^M Pa-PDT 
Go/Gi: 56.70% Go/Gi： 56.77% 
^ G2/M : 15.21% G2/M : 15.67% 
°： I S: 28.09% I S: 27.56% 
BL o— • 
o ^ ^B ^1 
, ; I L / ‘ | [ j " ' 
°- • , • • I • • • • f ^ ^ ^ ^ ^ ^ P ^ ^ h - x n n - ‘ t ^ ^ ^ ^ ^ " * ! * * ^ ^ ^ i i l l ^ • — 
23 40 • eo 80 1^0D -io I ‘ ‘ I I ' I ‘ I f f ^ ^ I ‘ I I I ^ T ^ ' I • I 
Ch^^p:-A) ^ ° 20 ^chanr^PE-A)80 °^° 120 
6 1 
0.8 nM Pa-PDT 1 i^M Pa-PDT 
Go/G, : 5 9 . 5 8 % Go/Gi： 6 0 . 1 6 % 
IG2 /M : 15 .91% ^ G2 /M : 10 .56% 
S : 2 4 . 5 1 % U S: 2 9 . 2 9 % 
� • I Sub-Gl: 12.55% 
I 
w 屋 墨 
] • • Dip 6 1 ^ n 面 Ap0pt0sis • • DpG2 H | • D,pG1 
• b ^ Dip S ^ H • Dip G2 
^ I ^ ^ ^ ^ ^ 一 
- j p ^ f # f f l | k . . . , ^ ^ ^ ^ i | » f i ^ f t ^ ^ ^ 
“ “ C h a ^ e f e " , P E - A , ^ ^ ' 湘 。 30 % : p ^ ； ^ 
H 
Pa conc Sub-Gi Phase 
, � 1 � Go/G, Phase (%) G2/M Phase (%) S Phase (%) ‘ 
( _ (%) 
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(H) 72 h after Pa-PDT 
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Figure 2.3 Temporal change in the cell cycle profile after Pa-PDT 
MCF-7 cells were treated with Pa-PDT (0- 1 ^iM) and fixed at time-points (D) 4 h, (E) 
16 h, (F) 24 h, (G) 48 h and (H) 72 h. Dark controls (Pa without photodynamic 
activation) of time-points (A) 24 h, (B) 48 h and (C) 72 h were included. After 
staining with propidium iodide, the samples were analyzed by flow cytometry to 
generate cell cycle profiles. Population counts were calculated by the software 
ModFit LT 3.0. Representative cell cycle profiles of at least 3 experiments were 
shown in each time-point. Tabulated data were expressed as the mean 士 standard 
deviation (SD). *p<0.05; "p<0.01; ***p<O.OOl. 
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2.3.4 Effect of Pa-PDT on cell cycle associated proteins. 
The effect of Pa-PDT on the protein levels of cyclin A, B1, D1 and E was 
investigated by Western blot analysis. MCF-7 cells were treated with 0-0.75 i^M of 
Pa-PDT and whole cell Iysates were harvested 24 h after treatment. The band 
intensity developed by the enhanced chemiluminescence detection kit is directly 
proportional to the amount of protein present in the sample and the house-keeping 
protein P-actin serves as the internal control for the assay. 
As shown in Figure 2.4, cyclin B1 and D1 levels were reduced by Pa-PDT in a 
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Figure 2.4 The effect of Pa-PDT on cell cycle-associated proteins. 
MCF-7 cells were treated with Pa-PDT ofO, 0.25, 0.5 and 0.75 ^iM. 24 h afterwards 
cells were lysed and total protein was extracted. Westem blotting was performed and 
the presence of specific protein was detected by ECL reagents and X-ray film. The 
house-keeping gene p-actin served as the internal control for protein normalization. 




Malignancy is characterized by the uncontrolled proliferation of cancer cells. 
Besides surgical resection, other cancer therapies, including radiation therapy, 
hormonal therapy and chemotherapy, involve the induction of cancer cell death by 
physical or chemical agents. Cell death can be triggered by different mechanisms 
while common ones include apoptosis, necrosis and autophagy (Kroemer et al. 2009). 
The photosensitizer pheophorbide a (Pa) demonstrated anti-proliferative effect upon 
photodynamic activation in several human cancer cell types including 
hepatocarcinoma cell line HepG2 and its multidrug resistant counterpart R-HepG2, 
n 
leukaemia cell line Jurkat, uterine sarcoma cell line MES-SA and breast 
adenocarcinoma cell lines MDA-MB-231 and MCF-7 (Lee et al. 2004; Tang et al. 
2006; Tang et al. 2009; Tang et al. 2009). The death mechanism induced by Pa-PDT 
was mainly via apoptosis in all cell lines tested, but cell cycle arrest was reported in 
addition to apoptotic features in MCF-7 cells (data not published). In order to have a 
more thorough understanding on the anti-proliferative effect of Pa-PDT, the 
time-dependent cell cycle arrest mediated by Pa-PDT in MCF-7 cells and the 
mechanisms involved were further investigated in this study. 
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/. Expression ofgrowth arrest andDNA damase inducible (GADD) senes 
Although the anti-proliferative effect of Pa-PDT has been demonstrated potent 
in various cancer cell types, the molecular targets of Pa-PDT remain unclear. Recent 
advances in microarray analysis facilitated the genome-wide expression profile 
elucidation and therefore, enabling the identification ofspecific pathways induced by 
various endogenous and exogenous conditions. In order to better understand the 
molecular targets of Pa-PDT on MCF-7 cells, mRNA microarray was performed 
using the GeneChip® Human Gene 1.0 ST Array by Affymetrix, an analysis 
providing whole-transcript coverage. The growth arrest modulators GADD family 
including GADD34, GADD45A, GADD45B，GADD45G and GADD153, was 
generally increased after 0.5 i^M Pa-PDT treatment as indicated by the positive L0g2 
ratio (Pa-PDT treated/Control) of normalized signals. As cell cycle is often 
deregulated in cancers, inhibition of cell cycle progression is also a potential strategy 
for cancer treatment apart from direct induction of cell death mechanisms (Shapiro 
and Harper 1999). 
The induction of GADD genes were confirmed by reverse transcriptase-
polymerase chain reaction (RT-PCR). However, the overall RNA quality and quaptity 
was found to be reduced with Pa-PDT dose from 0.5 i^M (equivalent to IC50) 
onwards (data not shown), therefore the dose for RT-PCR was lowered to 
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0.15-0.45 |aM. As mRNA is single-stranded and relatively fragile in nature, it may be 
more vulnerable to degradation upon cellular damage or early induction of cell death, 
thus giving rise to unsatisfactory RNA quality in high dose of Pa-PDT. As shown in 
Figure 2.2, the mRNA levels of GADD34, GADD45A, and GADD45G were 
increased dose-dependently with Pa-PDT while the extent of elevation in GADD153 
mRNA level was similar for tested doses. The mRNA level of GADD45B was not 
significantly affected by Pa-PDT. These results obtained from RT-PCR were 
consistent with that of mRNA microarray analysis. 
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ii. Cell cvcle analysis 
As previous studies found that over-expression of GADD genes would lead to 
growth arrest or apoptosis (Hollander et al. 2001), a temporal study was carried out 
to monitor the change in the cell cycle profile at different time-points after Pa-PDT. 
As shown in Figure 2.2，cell cycle profiles of MCF-7 cells did not show any 
significant change at 4 and 16 h after Pa-PDT of dose ranging from 0.1-1 ^iM. 24 h 
after Pa-PDT, G2/M cell cycle arrest was observed, as indicated by the statistically 
significant decrease in Go/Gi population at 0.8 and 1 ^M of Pa-PDT and an incjease 
in G2/M population at 0.6，0.8 and 1 i^M Pa-PDT. Population of S phase was not 
significantly affected. The G2/M arrest observed at 48 h post-Pa-PDT was more 
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obvious, with significant reduction in Go/Gi population for all doses of Pa-PDT, 
increased G2/M population at 0.4, 0.6 and 0.8 i^M Pa-PDT and no significant change 
in S phase. In addition to G2/M arrest, a sub-Gi peak representing sub-diploid DNA 
content was also observed in 1 |_iM Pa-PDT, indicating the occurrence of DNA 
fragmentation. 72 h after Pa-PDT, the dose-dependent increase in sub-Gi population 
dominated the cell cycle profile and G2/M arrest features were no longer observed. 
In summary, G2/M cell cycle arrest was observed at 24 and 48 h after Pa-PDT 
and DNA fragmentation occurred at 48 and 72 h after Pa-PDT in MCF-7 cells. 4 and 
16 h might not be adequate for cell cycle arrest to occur, as cell cycle modulators, for 
M 
instance GADD genes and cyclins, have to be activated or degraded to orchestrate 
the event of cell cycle arrest. Moreover, cells can only be arrested at the G2 
checkpoint when they intended to enter the M phase. The doubling time of MCF-7 
cells is 29 h, so a certain period of time is required for the cells to progress to the 
appropriate checkpoint before being arrested. By definition, cells being arrested in 
the cell cycle should be considered alive, as senescent or highly differentiated cells 
maybe arrested at Go phase under normal physiological conditions (Kroemer et al. 
2009). Direct evidence of cell death induced by Pa-PDT was demonstrated at 48 and 
72 h after treatment, as indicated by the sub-Gi peak in the cell cycle profiles. 
Sub-diploid DNA content refers to DNA fragmentation, the result of apoptosis or 
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necrosis. Our group previously demonstrated the induction of apoptotic pathway by 
Pa-PDT in MCF-7 cells (data not published). Apoptotic features including 
phosphatidylserine externalization, collapse of mitochondrial membrane potential 
and altered protein levels of apoptotic mediators (e.g. p53, caspases 9 and PARP) 
were detected. However, DNA fragmentation, a downstream event of apoptosis, was 
first reported in this study. Therefore, it is rational to believe that the sub-Gi peak of 
the cell cycle profiles corresponded to apoptotic cells. Although the change in G2M 
and Go/Gi population in the cell cycle profiles was statistically significant, the 
percentage changed was not very drastic. It suggested that G2/M cell cycle arrest may 
t* 
be an adjuvant instead of a dominant death pathway induced by Pa-PDT. 
Figure 2.3 (H) showed a dose-dependent increase in sub-Gi peak at 72 h after 
Pa-PDT. The G2/M population was significantly reduced by 0.6-1 i^M Pa-PDT, in 
contrast to the G2/M arrest observed in 24 and 48 h, suggesting that the cells being 
arrested at G2/M phase were more susceptible to DNA fragmentation. After Pa-PDT, 
cells progressed to the G2 phase and were arrested at the G： checkpoint as 
orchestrated by cell cycle regulators. As cells with diploid DNA content were 
relatively unstable, they were more prone to apoptosis. As a result, G2/M population _ 
underwent apoptosis preferentially, leading to the presence of sub-Gi population, 
reduced G2/M population and relative increase in percentage of Go/G| and S 
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population. 
As discussed above, the induction of apoptosis by Pa-PDT was demonstrated in 
several cancer cell types, with DNA fragmentation detected at 24 h after treatment. 
The cell line MCF-7 is deficient in caspase 3, the final caspase in which the intrinsic 
and extrinsic apoptotic pathways converge (Kagawa et al. 2001; Janicke 2009). 
Caspase 3 cleaves the inhibitors of the caspase-activated deoxyribonuclease (ICAD) 
and therefore leads to DNA fragmentation upon activation (Ghobrial et al. 2005). In 
the absence of caspase 3，ICADs have to be cleaved by alternative pathways or other 
classes of endonucleases have to be activated in order to execute DNA fragmentation, 
*« 
leading to the delayed appearance of sub-G| population although 
apoptosis-mediating events, such as cytochrome c release and mitochondrial 
membrane depolarization were detected as soon as 4 h after Pa-PDT treatment in 
MCF-7 cells. 
The effect of Pa alone (without light activation) on the cell cycle distribution of 
MCF-7 cells was also investigated. According to Figure 2.3 (A-C), no significant 
change in cell cycle profiles was observed after 24, 48 and 72 h ofPa treatment up to 
1 ^iM. It showed that the toxicity of Pa without light exposure was very low at the 
• • 
therapeutic dose for photodynamic therapy. Therefore, systemic side-effects of 
Pa-PDT can be kept minimal by limiting irradiation to the tumor region only. 
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iii. Protein levels of cvclins 
The effect of Pa-PDT on the protein levels of cyclin A, B1, D1 and E was 
investigated by Western blot analysis. With reference to Figure 2.4, the levels of 
cyclin B1 and D1 were reduced dose-dependently 24 h after Pa-PDT. Cyclin B1 is 
expressed predominantly during the G2/M phase, and it complexes with CDK1 to 
form the maturation-promoting factor (MPF). MPF promotes early events of mitosis, 
for instance chromatin condensation and spindle pole assembly (Chen et al. 2008). 
As cyclin B1 level was reduced after Pa-PDT treatment, free protein available for 
binding with CDK1 was reduced, therefore the transition from G： to M phase was 
n 
hindered, and detected as G2/M arrest by flow cytometry. 
Cyclin D1 activates CDK4 or CDK6 upon binding. The holoenzymes facilitate 
the progression from Go to Gi and Gi to S phase of the cell cycle (Sherr et al. 1994; 
Takahashi-Yanaga and Sasaguri 2008). Cyclin D1 level was reduced by Pa-PDT in a 
dose-dependent fashion, suggesting that Pa-PDT may cause a global slowing down 
of cell cycle progression although specific Go/G| and S phase arrest were not 
detected by flow cytometry. Moreover, cyclin D1 is known to be a proto-oncogene 
that gene amplification and protein over-expression are frequently observed in 
various malignancies including breast, esophageal, bladder and lung cancers (Hall 
and Peters 1996; Fu et al. 2004). Therefore cyclin D1 is also a target for cancer 
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chemotherapy and any agents that can repress cyclin D1 level is potentially 
beneficial for patients' survival (Barbieri et al. 2004). 
The levels of cyclin A and E were not significantly altered by Pa-PDT. Cyclin A 
binds with CDK2 and the complex is required during S phase (Vermeulen et al. 
2003). Cyclin E promotes the progression from Gi to S phase upon binging with 
CDK2. Pa-PDT did not cause reduction in cyclin A and E levels, suggesting that the 
treatment would not elicit S phase arrest. This speculation was validated by cell cycle 
analysis, with no S phase arrest features detected. 
*t 
iv. Implication of experimental results 
The anti-proliferative effect of Pa-PDT on MCF-7 cells was previously 
demonstrated, and the mechanisms involved were further investigated in this study. 
In summary, Pa-PDT causes cellular and DNA damage in MCF-7 cells, and therefore 
leads to the induction of GADD genes. GADD genes then in turn arrest the cells at 
the G2/M phase, aiming to provide time for damage repair as the cell's own 
protective mechanism. However, if the damage is too severe or irreversible, the cell 
undergoes self-destruction via apoptosis with DNA fragmentation as a haHmark 
feature. Moreover, reduction in cyclin B1 and D1 levels suggested that the 
anti-proliferative effect of Pa-PDT is attributed, at least partially, by the restricted 
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cell cycle progression. 
As one of the criteria of an ideal photosensitizer used in photodynamic therapy, 
it should possess low toxicity without light irradiation but strong photo-cytotoxicity 
in order to maximize cancer- killing effect but to minimize systemic toxicity (Huang 
2005). When MCF-7 cells were treated with Pa alone without photo-activation, no 
significant change in cell cycle distribution was observed up to 72 h. It suggested that 
Pa fulfilled the above criterion owing to its low dark toxicity within the therapeutic 
dose for photodynamic therapy. 
n 
The anti-proliferative effect of Pa-PDT was shown mainly mediated via the 
induction of apoptosis by previous works. Cell death mechanism involving GADD 
genes-mediated cell cycle arrest was first demonstrated in this study. The advantage 
of multiple death pathways involvement is that, the treatment can remain potent 
towards cancers with mutated death pathway modulators. For instance, this study 
demonstrated the ability of Pa-PDT to kill cancer cells with defective caspase 3, the 
final caspase leading to the execution ofDNA fragmentation. 
«• 
Cell cycle is often deregulated in cancer cells with favors towards proliferation 
(Malumbres and Barbacid 2007). As the function of cell cycle checkpoints is to 
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guarantee DNA fidelity, unscheduled cell division is associated with genome 
instability including mutations and chromosomal aberrations (Malumbres and 
Barbacid 2009). The existence of genetic variation among cancer cells increases the 
chance of multidrug resistance development under the selection pressure during the 
course of chemotherapy. As Pa-PDT was shown able to reinforce cell cycle 
regulation, other than the direct induction of cell death, it can potentially reduce 
tumorigenicity and chance of multidrug resistance development (Ma et al. 2009). 
Multidrug resistance (MDR) is a major obstacle encountered in cancer chemotherapy 
attributing to the majority of treatment failures (Longley and Johnston 2005). The 
n 
anti-proliferative effect of Pa-PDT on MDR cell lines was further investigated as 
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3.1.1 Clinical importance of multidrug resistance (MDR) 
Recent advances in the development of chemotherapeutic drugs have improved 
patient survival. However, multidrug resistance (MDR) continues to be a major 
impediment to effective anti-cancer chemotherapy. It is believed that MDR attributed 
to treatment failure in over 90% of patients with metastatic malignancies (Longley 
and Johnston 2005). 
MDR is the phenomenon that cancer cells develop the ability to evade the 
cytotoxic effects of a broad range of chemotherapeutic drugs by different 
mechanisms. Primary resistance refers to tumors with intrinsic resistance to 
n 
anti-cancer drugs prior to the introduction of chemotherapy and acquired drug 
resistance occurs when initially sensitive tumors eventually become non-responding 
or partially responding to anti-cancer drugs during the course of treatment. One 
property of such acquired resistance is that, the tumor usually not only exhibit 
resistance to the original drug(s) used, but cross-resistance to a broad spectrum of 
drugs sharing little similarity in chemical structures and action mechanisms, giving 
rise to MDR phenotype. 
• • 
3.1.2 Mechanisms of MDR 
MDR can be broadly classified into non-cellular and cellular based mechanisms 
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(Krishna and Mayer 2000; Lage 2008), a summary of classification can be referred to 
Figure 3.1. Non-cellular mechanism refers to the micro-environment of tumor 
growth. Poor vascularization of solid tumors can result in the reduction of drug 
access and thus cytotoxicity. Nutrients and oxygen deficiency can induce additional 
resistance mechanisms mediated by intracellular stress. 
Cellular based resistance mechanisms can be further divided into non-classical 
MDR and classical MDR. Non-classical MDR phenotypes include increased 
glutathione S-transferase activity, compensatory over-expression of topoisomerase 
I/II, alteration of apoptotic regulation and DNA repair systems. 
n 
Classical MDR, also know as transporter-based MDR, is the major mechanism 
involved in clinical MDR. The ATP-binding cassette (ABC) family of membrane 
transporters are of considerable clinical importance (Krishna and Mayer 2000). The 
human genome contains 49 ABC genes, arranged in seven subfamilies, designated as 
ABCA to ABCG (Vasiliou et al. 2009). ABC transporters utilize the energy released 
by ATP hydrolysis to move their substrates, including metal ions, peptides, sugars 
and hydrophobic compounds, across the plasma and also intracellular membranes 
against their electrochemical gradients. 一 
Among all transporters, P-glycoprotein (P-gp) encoded by the gene ABCB1 
(also known as MDR1), was known to be the most important factor mediating MDR 
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phenotype since its discovery in 1976 (Juliano and Ling 1976; Kartner et al, 1983). 
P-gp is a membrane-embedded drug extrusion pump that can actively transport drugs 
out of cells. P-gp demonstrates a typical cross-resistance pattem of MDR against a 
broad spectrum of drugs, particularly targeting on natural hydrophobic 
anti-neoplastic agents such as taxanes, anthracyclines and vinca alkaloids (Longley 
and Johnston 2005). Reduced intracellular drug concentration will in turn lower drug 
sensitivity. 
In general, anti-neoplatic agents usually have very narrow therapeutic window, 
meaning that the difference between the dose of achieving therapeutic effect and the 
n 
dose of causing toxic effect is very small. So, for a mild decrease in drug sensitivity 
of cancer, the dose required to eradicate the cancer may worsen the side-effects to a 
non-manageable clinical situation (Lage 2008). Therefore, if MDR can be better 
understood by the establishment of in vitro cell line model and overcome by the 
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Figure 3.1 Summary of multidrug resistance (MDR) mechanisms of anti-cancer 
chemotherapy. 
Intra-cellular drug concentration can be reduced by poor tumor vascularization, 
over-expression of ABC transporters or enhanced detoxification capacity. Cells can 
evade from chemotherapeutic drugs by modifying the targeted metabolic pathways, 
such as topoisomerase inhibition, apoptosis induction and formation of DNA 
adducts. 
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3.1.3 Development of MDR cell lines 
MDR cell lines were established either by enforced expression (transfection) of 
P"gp (Doyle et aI. 1998; Laberge et al. 2009) or repeated exposure of anti-cancer 
drugs (Harker and Sikic 1985; Tang et al. 2009). In this study, the latter protocol will 
be employed in the development of MDR cell line in order to better mimic the 
clinical scenario of chemotherapy. The cell line chosen was MDA-MB-231 (MDA), 
a metastatic, estrogen receptor (ER)-negative human breast adenocarcinoma cell line 
representing a late stage, hormone non-responsive disease. For ER positive breast 
cancers, hormone therapy is generally the most appropriate initial treatment owing to 
, t 
its higher tolerability. A population-based study showed that the median 
breast-cancer specific survival was dependent on ER status, which was 14 months in 
ER-negative cases and 32 months in ER-positive cases respectively (Dawood et al. 
2008). ER-negative cancers fail to respond to hormone therapy and first-line 
treatment protocol has to be switched to chemotherapy (Telli and Carlson 2009). 
However, as mentioned above, prolonged chemotherapy is prone to the development 
ofMDR. Therefore, MDA was chosen to be the candidate for MDR development, in 
order to establish an in vitro model demonstrating aggressive clinical behaviors 
«• 
including metastasis, hormone non-responsive and chemotherapy resistance. 
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3.1.4 Reversal of MDR by P-glycoprotein modulators 
During the decades after the discovery of P-gp and MDR, numerous researches 
were conducted in an attempt to abolish MDR. However, only a few were proven 
safe and effective clinically. Chemosensitization involves the co-administration of 
P-gp inhibitors in order to enhance intra-cellular accumulation of anti-cancer drugs. 
Unfortunately, the effective dose of P-gp modulators can exhibit severe and even 
life-threatening adverse effects due to the inherent toxicity and blockade of P-gp in 
normal tissues (Krishna and Mayer 2000). In a clinical study of a P-gp inhibitor 
verapamil, patients with P-gp-positive myeloma were chemosensitized to certain 
n 
extent. However, the response was short-lived and tumor cells ultimately became 
resistant to the chemosensitizers (Abbaszadegan et al. 1996). Therefore, the 
development of efficacious and yet safe P-gp modulators is an urgent need for the 
re-sensitization ofMDR cancers to chemotherapy. 
3.1.5 Therapeutic potential of Pa-PDT in treating MDR cancers 
In the past decades, the potential of photo-dynamic therapy (PDT) in treating 
cancers and reversing MDR has been evaluated by numerous studies (Capella and 
«• 
Capella 2003). PDT involves the administration of a photosensitive agent followed 
by light illuminationof the targeted area in the presence of oxygen. The two agents, 
photosensitizers and light (usually within visible light region), both possess very low 
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cytotoxicity separately. Thus, the location of PDT action can be finely controlled by 
limiting irradiation to affected area only for minimizing systemic toxicity. 
The anti-cancer efficacy of PDT was well documented and several 
photosensitizers were approved for clinical use including porfimer sodium 
(Photofrin®), 5-aminolevulinic acid and temoporfin (Huang 2005). Moreover, several 
research groups have demonstrated that PDT can serve as P-gp modulators to 
re-sensitize MDR cell lines including leukemia, fibrosarcoma, osteosarcoma and 
mammary tumors (Kessel et al. 1995; Wainwright et al. 1999; Kusuzaki et al. 2000; 
Li et al. 2001; Teiten et al. 2001). The down-regulation of P-gp was suggested to be 
mediated by the oxidative stress generated by PDT (Gibson et al. 1995). 
The anti-neoplastic effect of Pa-PDT was demonstrated on liver, breast and 
uterine cancers both in vitro and in vivo. Pa-PDT was shown to be able to inhibit 
P-gp-mediated MDR via JNK pathway activation in human hepatocarcinoma cell 
line R-HepG2 (Tang et al. 2009). So the aim ofthis study is to establish a multidrug 




3.2 Materials and Methods 
3.2.1 Materials 
3.2.1.1 Cell line 
The human breast adenocarcinoma cell line MDA-MB-231 (MDA) was 
purchased from the American Type Culture Collection (Baltimore, MD, USA). It was 
derived from the pleural effusion as the site of metastasis of a 51 years old female 
Caucasian. 
3.2.1.2 Cell culture medium, supplements and buffers 
Fetal bovine serum and antibiotics (penicillin and streptomycin) were added to 
GIBCO® RPMI 1640 medium to constitute complete medium. Trypsin-EDTA and 
phosphate-buffered saline were used in the subculture of cell lines. The purchase 
information and ingredients can be referred to Chapter 2. 
3.2.1.3 Cell viability assay reagents 
I. Doxorubicin 
Doxorubicin was purchased from Wako Pure Chemical Industries. Stock 
solution of lmM was prepared by adding sterilized de-ionized water and stored at 
-20。C. 
• • 
II. Methvlthiazoletetrazolium (MTT) ‘ 
3-(4,5-Dimethyl-2-thiazolyl)-2 ,5-diphenyl-2H-tetrazolium bromide (MTT) 
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powder was bought from USB Corporation. 4 mg/ml working solution was prepared 
by dissolving the powder in sterile PBS and stored at 4 °C under subdued light. 
III. Dimethyl sulfoxide DMSO 
DMSO was purchased from Sigma-Aldrich Co and stored at room temperature 
in brown bottle. 
3.2.1.4 Gene expression assay reagents 
I. RNA isolation 
RNase AWAY was purchased from Molecular BioProducts to remove RNase 
and DNA contaminants. NucleoSpin® RNA II Total RNA Isolation kit was purchased 
from MACHEREY-NAGEL. 
II. Reverse transcription (RT) 
TaqMan® Reverse Transcriptase Reagents was purchased from Applied 
Biosystems. 
III. Polymerase chain reaction (PCR) 
Taq PCRx DNA Polymerase was purchased from Invitrogen Life Science. 
Primers for the amplification of p-actin and ABCB1 were purchased from Invitrogen 
m» 
Life Science. The primer sequences were shown below. ‘ 
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cDNA amplified Strand Sequence (5，to 3，) 
Sense GGCCGGGACCTGACAGACTAC 
卩-actin Antisense GGGGCCGGACTCATCGTACTC 
Sense GGAACTCAGCTCTCTGGTGG 
ABCg 1 ~^t i sense CTTCTCTGGCTTTGTCCAGG 
IV. Agarose gel electrophoresis 
UltraPure™ agarose powder (Invitrogen Life Science) and 2 i^l ethidium 
bromide (Pharmacia Biotech, 10 mg/ml) were dissolved in IX TBE buffer (Genesee 
Scientific, Apex TBE Buffer containing Tris base, boric acid and EDTA) to constitute 
2% agarose gel. GeneRuler'M 100bp DNA ladder (Fermentas) was used as the DNA 
marker. 6X sample loading buffer was made by dissolving 0.25% w/v bromophenol 
blue and 40% w/v sucrose in de-ionized water and stored at - 2 0 � C . 
n 
3.2.2 Methods 
3.2.2.1 Cell line propagation and subculture 
MDA cell line was maintained in RPM1 1640 medium supplemented with 10% 
fetal bovine serum (FBS) and 1% v/v antibiotics (PS). The cell line was cultured in 
75 or 150 cm~ tissue culture flask (IWAKI) and incubated at a 37。C humidified 
incubator with 5% CO2 supplied. 
• • 
For the subculture of MDA cells, the medium was discarded and the adherent 
cells were rinsed with pre-warmed PBS. 1.5 ml (for 75 cm" culture flask) or 3 ml (for 
150 cm" culture flask) trypsin-EDTA solution was added and incubated at 37 °C for 
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1 min. Complete RPMI medium was added to cease trypsinization. 
3.2.2.2 Drug-resistance development 
MDA cells were cultured in 75 cm" tissue culture flask. For the first round of 
doxorubicin (Dox) treatment, 0.1 |aM Dox was added to the culture flask. 48 h 
afterwards, the medium was replaced by Dox-free culture medium. The medium was 
changed every two days to remove any dead cells or debris. When cell morphology 
and proliferation resumed normal, another round of Dox treatment of higher dose 
was repeated. 
3.2.2.3 Measurement of cell viability - MTT reduction assay 
MDA cells of 2 x 10^  were seeded onto each well of a 96-V^ell culture plate 
(IWAKI) and incubated for 24 h in a humidified incubator with 5% CO2 supplied to 
allow attachment. After the addition of appropriate concentrations of doxorubicin, 
the cells were incubated at 37 °C for another 48 h. After incubation, culture medium 
was aspirated and 40 \i\ MTT solution (4 mg/ml in PBS) was added to each well. The 
plate was incubated for 2 h at 37 °C. The MTT solution was removed and replaced 
with 50 \x\ DMSO to dissolve the formazan dye formed. The absorbance at 540 nm 
was measured by a microplate reader (Bio-Rad). The percentage of cell viability was 
• • 
calculated as follows: -
% viability = [OD540 oftest sample/ OD540 ofcontrol] x 100% 
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3.2.2.4 ABCB1 expression assay- RT-PCR 
I. RNA isolation 
3 X 10^  cells were seeded on a 100 mm culture dish (IWAKI) for 24 h to allow 
adhesion. Cells were harvested by trypsinization and RNA was extracted by the RNA 
NucleoSpin® RNA II Total RNA Isolation kit according to the user manual. 
II. RNA Quantification 
RNA concentration was determined by measuring the absorbance at 260 nm 
(A260) by spectrophotometer (Eppendorf). The A260/ A280 ratio ranged from 1.8 to 2.4. 
The RNA was stored at -80。C for not longer than a month. “ 
III. Reverse transcriptase- polymerase chain reaction (RT-PCR) 
Semi-quantitative analysis of the mRNA levels of the ABCB1 and the 
housekeeping gene p-actin was carried out by RT-PCR with the number of cycles at 
which the band intensity increased linearly with the amount of mRNA present. 
500ng of total RNA was reverse transcribed to complementary DNA (cDNA) 




1 Ox Reaction Buffer 5 
MgCb(25 mM) 11 
dNTP(lOmM) 10 
Random Hexamer (50 ng/ i^l) 1.25 
Oligo d(T)i6(50 ^iM) 1.25 
RNase Inhibitor (20 U/ \x\) 1 
Reverse Transcriptase (50 U/ i^l) 0.5 
dH.0 ^ 
——： Atotal of20 
RNA sample 
The program of the thermo-cycler (GeneAmp® PCR System 9700, Applied 
Biosystems) is as follows. 
9 5 ° C 
I 5 m i n \ 
3 7 °C / \ 
2 5 ¾ / ~ " ^ — ^ \ 
f 6 0 m i n \ 4 ¾ 
1 0 m i n ^ ^ “ 
cDNA samples obtained were stored at -20 °C before the amplification of the 
targeted genes, ABCB1 and p-actin by PCR. The reagents per PCR were as indicated 
below: 
Volume (|il) 
10x Reaction Buffer(-MgCl2) 2 
MgCl2 (50 mM) 0.6 
dNTP (2.5 mM) 1.6 
Taq DNA polymerase (5 U/^il) 0.1 -
dH2O 12.7 
cDNA sample 2 
Primer Mix (Forward+ Reverse) 1 
9 0 
The program of the PCR reaction is as follows. 
35 Cycles 
9 4 ¾ j 9 4 ¾ 
5 m i n | 5 0 s \ 7 2 � C ： 7 2 � C 
\ 5 8 ¾ / 5 0 s i 10 m i n \ 
5 � s \ 4 - C 
: 00 
The PCR products were resolved by gel electrophoresis. 2% agarose gel was 
pre-stained with ethidium bromide and visualized by a ultra-violet light cabinet 
(Alpha Innotech Corporation). 
3.2.2.5 Doxorubicin uptake assay 
n 
1 X 10^  cells were seeded on a 60 mm culture dish (IWAKI) for 24 h to allow 
adhesion. 4 )_iM doxorubicin was added to the cells and incubated at 37。C for 4 h. 
Then the cells were trypsinized and washed with PBS twice. The samples were 
analyzed by flow cytometer (BD FACSCanto) and the software WinMDI. 
3.2.2.6 Pheophorbide a uptake assay 
1 X lC)6 cells were seeded on a 60 mm culture dish (IWAKI) for 24 h to allow 
adhesion. 1 or 3 i^M pheophorbide a (Pa) was added to the cells and incubated at 37 
。C for 4 h. Then the cells were trypsinized and washed with PBS twice. The samples 
were analyzed by flow cytometer (BD FACSCanto) and the software WinMDl. 
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3.2.2.7 Statistical analysis 
Experimental results showed were either representative or averaged data of at 
least 3 independent experiments with consistent results. For Dox uptake assay, data 
were expressed as mean 士 standard deviation (SD). For cell viability assay, in each 
trial, a mean was obtained from 6 replicates. An average value of means was 
calculated from 3 independent trials. Therefore the graphical representation was 





3.3.1 Cytotoxicity of doxorubicin on MDA and MDA-R cells 
With the intermittent exposure to doxorubicin (Dox) described in the 
methodology, 10 rounds of treatment were completed with Dox concentration 
ranging from 0.1 to 2 i^M. 
In order to assess the acquisition of drug resistance, MTT assay was performed 
to determine the dose-response relationship between Dox and the partially resistant 
MDA cells (MDA-R).The lC50 ofthe 5山 round MDA-R and 10'^  round MDA-R was 
found to be 1.31 |iiM and 2 .28 i^M. In comparison with the IC50 of 0.76 i^M in the 
parental MDA cells, the 10''^  round MDA-R cells acquired a 3'-fold increase in 
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Figure 3.2 Cytotoxicity of doxorubicin on MDA and MDA-R cells. 
Cell survival was assessed by MTT assay 48 h after Dox treatment of different 
concentrations. The IC50 of the (A) parental MDA cells, (B) 5'^  round MDA-R cells 
and (C) 10th ^^^^^ MDA-R cells was found to be 0.76 ^M, 1.31 i^M, and 2.28 i^M 
respectively. Each point was expressed as the mean of 3 independent experiments, 
each consisted of 6 replicates 士 SEM. 
• “ 
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3.3.2 mRNA expression ofABCBl (P-glycoprotein) in MDA and MDA-R cells 
Anthracyclines, such as doxorubicin, are known inducers of P-glycoprotein 
(P-gp) encoded by the gene ABCB1 (Bidwell et al. 2007). Semi-quantitative RT-PCR 
was carried out to determine the expression level of ABCB1 in MDA-R and parental 
MDA cells. 
A weak up-regulation of ABCB1 was observed in MDA-R compared with the 
parental MDA cells with p_actin, a housekeeping gene as an internal control. A 
commercially available multi-rug resistant (MDR) and parental pair of uterine 
sarcoma cell lines were also included in the assay. MDR cell line MES-SA/Dx5 (Dx5) 
was established by repeatedly exposing the parental cell-line MES-SA (SA) to Dox. 




MDA MDA-R SA Dx5 
ABCBi ——• ^ ^ ^ m n n m m u m m m ^ 
~ ~ • U j j j l ^ ^ ^ l ^ ^ ^ ^ ^ ^ ^ 
Figure 3.3 mRNA expression ofABCBl (P-glycoprotein) in MDA, MDA-R, SA 
and Dx5 cells. 
mRNA was isolated and reverse transcribed into cDNA. cDNA was amplified and 
the PCR product was separated by 2% agarose gel pre-stained with ethidium bromide. 





3.3.3 Doxorubicin uptake by MDA and MDA-R cells 
P-glycoprotein functions as a unidirectional efflux pump that can extrude 
tanxanes and anthracyclines including doxorubicin (Selbo et al. 2006). The cellular 
uptake of Dox by MDA-R and parental MDA was assessed by flow cytometry. As 
Dox itself possess florescent property, when cells were exposed to Dox and washed, 
the extent of Dox internalization can be detected by the fluorescence intensity. 
After 4 h treatment with 4 i^M Dox, 87.0% ofMDA-R cells showed internalized 
Dox, which was lowered compared with 94.4% in parental MDA cells. Only 8.3% of 
MDR variant Dx5 cells showed internalized Dox compared with 98.7% in the 











































































































































































































































































Figure 3.4 Doxorubicin uptake by MDA, MDA-R, SA and Dx5 cells. 
MDA, MDA-R, SA and Dx5 cells were treated with 0 or 4 i^M Dox for 4 h. Cells 
were then harvested and intracellular fluorescent intensity was analyzed by flow 
cytometry. Blue and red peaks corresponded to control or 4 |iM Dox treatment 
respectively. Ml showed the population of cells with internalized Dox and it was 
found to be 94.4 土 2.3o/o in (A) MDA cells, 87.0 士 2.8% in (B) MDA-R cells, 98.7 土 
2.5% in (C) SA cells, and 8.3 士 3.9o/o in (D) Dx5 cells expressed in mean of3 trials 土 





3.3.4 Circumvention of drug resistance in MDA-R cells by Pa-PDT 
In order to investigate whether the acquisition of Dox resistance would result in 
the resistance to Pa-PDT, MTT assay was performed to determine the dose-response 
relationship between Pa-PDT and the partially resistant MDA cells (MDA-R). The 
IC50 of the parental MDA cells and 10"^  round MDA-R cells was found to be 0.51 
l_iM and 0.57 i^M respectively, meaning that the acquisition ofDox resistance did not 
confer the resistance to Pa-PDT, indicating the ability of Pa-PDT to circumvent the 
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Figure 3.5 Cytotoxicity of Pa-PDT on MDA and MDA-R cells. -
Cell survival was assessed by MTT assay 24 h after photo-activation of Pa of 
different concentrations. The IC50 of the parental MDA (A) and 10^ '' round MDA-R 
(B) was found to be 0.51 i^M and 0.57 i^M respectively. Each point was expressed as 
the mean of3 independent experiments, each consisted of 6 replicates 士 SEM. 
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3.3.6 Pheophorbide a uptake by MDA and MDA-R cells 
The cellular uptake ofPa by MDA-R cells and parental MDA cells was assessed 
by flow cytometry in order to investigate the effect of acquisition of Dox resistance 
on Pa accumulation. Pa itself is a fluorescent molecule, exhibiting red fluorescent 
upon excitation. Therefore the extent of Pa internalization can be detected by the 
flow cytometry. 
After 4 h treatment with 1 or 3 ^M Pa, cells demonstrated elevated fluorescent 
intensity owing to the accumulation of Pa. The intrinsic fluorescent intensity 
observed in the Pa-free control MDA-R cells was lower compared with the parental 
MDA cells (Figure 3.6 blue peaks). Despite that, the general pattern of peak shifting 
after Pa treatment was similar in both parental MDA and MDA-R cells. 
• • 
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Figure 3.6 Pheophorbide a uptake by MDA and MDA-R cells. 
MDA and MDA-R cells were treated with 0，1 or 3 ^M Pa for 4 h. Cells were then 
harvested and intracellular fluorescent intensity was analyzed by flow cytometry. 
Blue, red and green peaks corresponded to control, 1 and 3 ^iM Pa treatment 
respectively. Results shown are representative data o f3 independent experiments. 
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3.4 Discussion 
Multidrug resistant (MDR) cell line can be established by repeatedly exposing 
the parental cell line to one or more cytotoxic agents either persistently or 
intermittently (Uozurmi et al. 2005; Rajkumar and Yamuna 2008; Labbozzetta et al. 
2009). 
Doxorubicin (Dox), a kind of anthracyclines, is a commonly used first-line 
chemotherapeutic agents for various types of malignancies (Telli and Carlson 2009; 
Zagouri et al. 2009). Dox itself, however, is also a known inducer of ABCB1 which 
encodes for P-glycoprotein, a well-studied MDR-associated ATP-binding efflux 
pump (Bidwell et al. 2007). For these reasons, Dox was commonly used as the 
anti-cancer drug for MDR development. 
ln this study, the first round of Dox treatment involved the addition of 0.1 i^M 
Dox to MDA cells. 48 h afterwards, the medium was removed and replaced by 
Dox-free culture medium. A higher dose of Dox was added when cell morphology 
and proliferation resumed normal. In total, 10 rounds of treatment were completed 
with Dox concentration ranging from 0.1 to 2 i^M. 
«• 
In order to investigate whether repeated Dox treatment would lead to the 
acquisition of resistance, MTT assay was performed to assess the dose-response of 
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Dox. As seen in Figure 3.2, cell viability decreased in a dose-dependent manner with 
increasing concentration of Dox. Compared with the IC50 of 0.76 ^M in the parental 
MDA cells, the IC50 of the 5^ '' round MDA-R cells and 10"�round MDA-R cells was 
increased 1.7 and 3-fold to 1.31 i^M and 2.28 i^M respectively. 
Previous work has demonstrated the over-expression of ATP-binding cassette 
(ABC) family of membrane transporters, especially P-gp, is a clinically important 
determinant of MDR (Krishna and Mayer 2000; Leonard et al. 2003; Lage 2008). 
MDR mediated by the over-expression ofP-gp was the commonality among several 
Dox-derived MDR variant cell lines including uterine sarcoma MES-SA/Dx5 
(Harker and Sikic 1985), hepatocarcinoma R-HepG2 (Tang et al. 2009) and 
mammary adenocarcinoma MCF-7R (Labbozzetta et al. 2009). The ability ofDox in 
inducingABCBl expression was also demonstrated in vivo (Abolhoda et al. 1999). 
Reverse transcriptase-polymerase chain reaction (RT-PCR) was carried out to 
investigate whether the acquisition of Dox resistance in MDA-R cells was attributed 
by the up-regulation of ABCBl,which encodes for P-gp. Compared with the parental 
MDA cells, MDA-R cells showed a mild up-regulation of ABCB1 as seen in Figure 
3.3. The up-regulation of ABCB1 was much more drastic in the commercially 
«• 
available MDR variant uterine sarcoma cell line MES-SA/Dx5. P-gp functions as a 
unidirectional efflux pump to extrude a variety of hydrophobic molecules such as 
• 
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tanxanes, vinca alkaloids and anthracyclines including Dox (Selbo et al. 2006). As a 
mild up-regulation of ABCB1 was observed, Dox uptake by MDA and MDA-R cells 
was assessed by flow cytometry. 
After exposing to 4 ^M Dox for 4 h, percentage of cells with internalized Dox 
was found to be 94.4% in parental MDA cells and reduced to 87.0% in MDA-R cells. 
In comparison, 8.3% of MDR variant Dx5 cells showed internalized Dox, which 
demonstrated a more drastic reduction when compared with 98.7% in the parental SA 
cells. 
Consistent results were obtained from RT-PCR and Dox uptake assay. For 
MDA-R cells, the mild ABCB1 mRNA up-regulation would lead to a gentle increase 
in the gene product P-gp, which in turn, would lead to the extrusion of its substrate 
Dox. A reduction in the intracellular drug availability would result in the increased 
tolerance to Dox. On the other hand, strong up-regulation of ABCB1 was observed in 
Dx5 compared with the parental SA cells. Thus, the majority of cells showed very 
low intracellular Dox level, attributed by the effective extrusion by P-gp. 
Although certain features ofMDR, including increased drug tolerance, ABCB1 
m» 
up-regulation and reduced Dox uptake were observed in the partially resistant 
MDA-R cell line, the features were not very prominent compared with other existing 
• 
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MDR cell lines. However, owing to the low therapeutic index of most anti-cancer 
drugs, even a weak decrease in the drug sensitivity can manifest a clinically 
drug-resistant feature (Lage 2008). Therefore, the MDA-R cells established in this 
study still possess considerable value in understanding the mechanism of MDR and 
the development of effective regimen. 
In previous studies, some researchers established their MDR cell lines by 
enforced expression (transfection) of P-gp, while some developed their MDR cell 
lines by repeated exposure to Dox either persistently or intermittently (Bradley et al. 
1989). Both protocols of Dox treatment were attempted in this study, however, MDA 
cells failed to survive under persistent Dox at the concentration as'low as 10 nM. For 
intermittent treatment, the recovery after 48 h Dox exposure could be longer than a 
month. Such long duration might weaken the accumulative effect of repeated 
exposure. Although MDR development protocols basically share similar rationale, 
the success ofMDR development is still dependent on a number of factors. 
The cell line MDA was originated from the pleural effusion derived from a 
metastatic breast carcinoma. It was an in vitro model of late stage of disease, in 
which certain features of normal mammary epithelium, such as the expression of 
• • 
estrogen receptor, was lost (Cailleau et al. 1978). The late stage and highly 
differentiated property may confer lower inducibility of genes. 
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In normal physiology, P-gp is expressed in the epithelia of the liver, kidney, 
uterus and intestine. The presence of P-gp in these tissues was believed to play a 
protective role in the mediation of xenobiotic efflux (Krishna and Mayer 2000; Kuo 
2009). Complicated mechanisms are involved in the induction of P-gp. Retinoids, 
sphingomyelin, Ras and PI3K-mediated signaling pathways were shown to be 
regulators of P-gp expression. So the induction machineries of P-gp may be more 
effective in tissues designated for its expression (Stavrovskaya and Stromskaya 
2008). 
Moreover, individuals may respond differently to the same drug (Gottesman 
2002). In a cohort study, 50 healthy volunteers administrated an ABCB1 inducer, 
which was proven potent in vitro. When the ABCB1 mRNA level from peripheral 
lymphocytes was analyzed, an increase was observed in 58% of the individuals, 
while a decrease was observed in 42% of the individuals although the serum 
concentration ofthe inducer was not significantly different (Asghar et al. 2002). This 
research demonstrated that the induction of P-gp can be greatly influenced by 
individual variation. 
• • 
In order to evaluate the potential of Pa-PDT in circumventing the drug 
resistance in MDA-R cells, cytotoxicity assay of Pa-PDT was performed on 10出 
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round MDA-R cells to investigate whether the acquisition of Dox resistance would 
result in the resistance to Pa-PDT. According to Figure 3.5, the cell viability 
decreased in a dose-dependent manner with increasing dose of Pa-PDT, with IC50 of 
0.51 i^M in parental MDA cells and 0.57 ^M in 10'丨、round MDA-R cells, lt showed 
that the anti-cancer effect of Pa-PDT was not significantly abrogated by the 
acquisition of Dox resistance or ABCB1 up-regulation. Besides, Figure 3.6 showed 
that the extents of Pa internalization after 4 h incubation with 1 and 3 i^M Pa were 
similar in the parental MDA and the MDA-R cells, indicating that Pa uptake was not 
abrogated by the acquisition ofDox resistance. 
These results were consistent with previous finding “showing Pa-PDT 
demonstrated anti-proliferative effect on both parental HepG2 and the MDR, ABCB1 
over-expressing variant R-HepG2 cells (Tang et al. 2009). As Pa is not a substrate of 
the unidirectional efflux pump P-gp, up-regulation of ABCB1 does not result in the 
extrusion of Pa. Therefore Pa-PDT is able to circumvent P-gp-mediated MDR 
pheonotype. 
In summary, the above results showed that certain degree of drug resistance was 
• • 
acquired after repeated Dox treatment, which was mediated, at least partially, by the 
up-regulation of ABCB1 to lower the intracellular Dox availability. Cytotoxicity of 
• 
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Pa-PDT was demonstrated similar in both parental MDA and MDA-R cells, 
indicating that the acquisition of Dox resistant or up-regulation of ABCB1 did not 
confer resistance to Pa-PDT. It implied that Pa-PDT would still be an effective 
regimen for human breast cancers which had acquired MDR mediated by the 
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4.1.1 Clinical limitations of doxorubicin as chemotherapeutic drug 
Chemotherapy is one of the standard treatment protocols in combating with 
cancers. Among numerous anti-neoplatic agents, doxorubicin (Dox) is one of the 
most commonly prescribed drugs which has been shown potent for a variety of 
malignancies over the past decades (Gilleron et al. 2009; Emanuelov et al. 2010). 
Dox is a DNA intercalating agent which stabilizes the topoisomerase II-DNA 
complex, thus inhibiting replication. Despite of the strong anti-neoplastic property 
towards cancer cells, the clinical effectiveness of Dox in chemotherapy is limited by 
two main obstacles discussed below. ^ 
I. Cardiac toxicity 
Cumulative dose of Dox is known to be prone to myocardial dysfunction. 
Previous in vitro, in vivo and well as clinical researches have demonstrated a 
dose-dependent acute cardiac injury and chronic heart failure associated with the use 
of Dox. The mechanism by which Dox causes cardiomyopathy is not exactly known, 
but it is believed that the cardiotoxic effect was mediated by the Dox-derived 
•« 




II. Development of resistance 
As discussed in Chapter 3, prolonged use of Dox can lead to the development of 
multidrug resistance in cancer cells. Dox is an inducer as well as a substrate of the 
MDR-associated ATP-binding efflux pump P-glycoprotein (P-gp) encoded by the 
gene ABCB1. Once MDR is acquired by cancer cells, the cancer may become 
irresponsive to a broad spectrum of structurally and functional diverse drugs, leading 
to failure ofchemotherapy (Longley and Johnston 2005; Bidwell et al. 2007). 
Therefore, new treatment options are needed to improve the clinical efficacy of 
Dox, aiming at palliating cardiotoxicity by reducing the dose of Dox used, as well as 
circumventing the P-gp-mediated MDR. ln this study, the potential of combination 
therapy as the new treatment option was evaluated. 
4.1.2 Clinical limitations of photodynamic therapy 
In the past decades, numerous researches have demonstrated the potency of 
PDT in treating malignancies, and several photosensitizers including Photofrin® 
and 5-aminolaevulinic acid were approved for the clinical use in treating cancers as 
well as non-malignant skin lesions (Marmur et al. 2004). Satisfactory clinical results 
•« 
were obtained in the use of PDT in treating superficial tumors. However, PDT 
remains suboptimal for large, refractory and deeper tumors (Marmur et al. 2004; 
• 
115 
Sinha et al. 2006). It was suggested this limitation was attributed by shielding effect 
or hypoxic condition within the solid tumors (Herzog et al. 1994). As the cytotoxicity 
of PDT is mainly mediated by the generation of reactive oxygen species (ROS) 
including superoxide ion, hydrogen peroxide and hydroxyl radical upon light 
activation (Henderson and Dougherty 1992; Sharman et al. 2000), either light 
shielding or hypoxia will cause a reduction of ROS generation and thus abolishment 
of PDT-mediated cytotoxicity. Sub-lethal damages can be repaired by the tumor cells 
as a rescue response. The surviving cells that managed to evade from PDT may 
eventually cause a local relapse or distant metastasis, rendering the treatment less 
effective (Macdonald and Dougherty 2001). “ 
For these reasons, PDT alone may only serve as palliative cancer treatment in 
clinical practice, and complete cure after single treatment was seldom achieved in 
deeper tumors (Kennedy et al. 1996; Waidelich et al. 2001). One of the more 
promising applications ofPDT is to treat the tumor bed after surgical resection ofthe 
tumor as a sterilization procedure (Abulafi et al. 1997). Clearly, new approaches in 
applying PDT are needed to improve its clinical potency against cancers. In this 
study, the potential of combination with PDT and one of the conventional cancer 
therapies, namely chemotherapy, was evaluated as a means to augment the efficacy 
in overall treatment outcome. 
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4.1.3 Combination therapy with Dox and Pa-PDT 
Owing to the complex nature of cancer development and progression, it is 
believed that no single therapeutic modality is perfectly curative. Therefore, 
combination regimens are generally accepted to be more effective in treating 
malignancies (Sinha et al. 2006). Combination therapy involves the simultaneously 
administration of two anti-neoplastic agents and it is beneficial for patients only if 
synergism is observed in the cytotoxicity of the two agents. Otherwise, sequential 
single-agent chemotherapy is preferred as a result of more favorable toxicity profile 
(Telli and Carlson 2009). The major strategy in choosing the combination candidates 
is to make sure they are not cross-resistant and do not produce overlapping toxicity 
(Schwartz 2009). 
In this regard, photodynamic therapy (PDT) is a potential regimen for 
combination therapy with Dox. Firstly, PDT itself is a localized treatment that 
possesses minimal systemic toxicity. Although the photosensitizer itself may not 
exhibit strong tumor specificity, the site of photodynamic action can be finely 
controlled by confining light irradiation to lesion region only (Bellnier et al. 2006; 
Busch et al. 2009). Secondly, the general cytotoxic mechanism of PDT is mediated 
_ 
by the generation of ROS, which is different form the DNA intercalation of Dox. As 
the two agents exhibit cytotoxicity via different mechanisms, they are less likely to 
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share cross-resistance. 
4.1.4 Uterine sarcoma cell line Dx5 as in vitro model for combination therapy 
A multidrug resistant (MDR) cell line is preferred for the study of combination 
therapy between Pa-PDT and Dox. As discussed in Chapter 3，over 90% 
chemotherapy failure in metastatic malignancies was attributed by MDR (Longley 
and Johnston 2005), Chemotherapeutic drugs generally possess very narrow 
therapeutic window, so even for a mild decrease in drug sensitivity of cancer, the 
dose required to eradicate the cancer may significantly worsen the side-effects 
associated (Lage 2008). Therefore, any combination regimen that can potentiate Dox 
cytotoxicity would be particularly beneficial to patients with MDR malignancies. 
As the MDA-R cell line developed as described in Chapter 3 was only mildly 
resistant to Dox, a commercially available multidrug resistant uterine sarcoma cell 
line MES-SA/Dx5 (Dx5) was chosen as the in vitro model for the study of 
combination therapy with Pa-PDT and Dox. 
Uterine sarcomas comprise 1% of all gynaecological malignancies and 4-9% of 
all uterine cancers (Zagouri et al. 2009). Although the incidence was relatively low 
«• 
compared with breast cancers, the disease usually exhibits highly aggressive clinical 
behaviors, for instance, high propensity of local recurrence and distant metastasis 
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(Papadimitriou et al. 2007). A retrospective analysis showed that radiotherapy 
improved local control, but had little benefits on overall survival (Nemani et al. 
2008). Owing to the rarity, aggressive clinical behaviors and lack of pre-invasive 
prognosis, current treatments have reached a plateau in terms of survival benefit. 
Chemotherapy is one of the primary treatments for uterine sarcomas while Dox 
is still the most commonly prescribed first-line chemotherapeutic drug with 25% 
response rate (Amant et al. 2009). As mentioned above, prolonged use of Dox is 
prone to cardiotoxicity and development of MDR. Therefore, new modalities to 
effective treatment of uterine sarcoma are craved and MDR uterine sarcoma cell line 
Dx5 can serve as a suitable in vitro model in testing the combination therapy with 




4.2 Materials and Methods 
4.2.1 Materials 
4.2.1.1 Cell line 
The human uterine sarcoma cell line MES-SA (SA) was purchased from the 
American Type Culture Collection (Baltimore, MD, USA). It was derived from a 
poorly differentiated uterine sarcoma of a 56 years old female Caucasian. 
The cell line MES-SA/Dx5 (Dx5) was the multi-drug resistance variant of SA 
purchased from the American Type Culture Collection (Baltimore, MD, USA). It was 
established by growing SA cells in the presence of increasing concentrations of 
doxorubicin. It has high levels of ABCB1 mRNA and P-glycoprotein expression. 
4.2.1.2 Cell culture medium, supplements and buffers 
I. Dulbecco's Modified Eagle's Medium (DMEM) 
GlBCO® DMEM powder was purchased from Invitrogen Life Science. 3.7 g 
sodium bicarbonate (Na2CO3) was added to each liter of DMEM during medium 
preparation. The pH of the solution was adjusted to 7.2 before being passed through 
a 0.22 i^m membrane filter (Millipore Express® PLUS) for sterilization. 
II. Other reagents 
• • 
Fetal bovine serum and antibiotics (penicillin and streptomycin) were added to 
DMEM to constitute complete medium. Trypsin-EDTA and phosphate-buffered 
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saline were used in the subculture of cell lines. The purchase information and 
ingredients can be referred to Chapter 2. 
4.2.1.3 Anti-cancer drugs 
I. Doxorubicin 
Doxorubicin (Dox) was purchased from Wako Pure Chemical Industries. Stock 
solution of 1 mM was prepared by adding sterilized de-ionized water and stored at 
-20。C. 
II. Pheophorbide a (Pa) 
Pheophorbide a was purchased from Frontier Scientific. 4 m M stock solution of 
pheophorbide a was prepared by dissolving Pa powder in ethanol (Scharlau) and then 
dehydrated dimethyl sulfoxide (DMSO, Sigma-Aldrich Co) in the v/v ratio 1:9 and 
stored at - 2 0 � C under subdued light. Pa was diluted to the desired concentration for 
the assays using complete DMEM and filtered by 0.22 i^m syringe filter (Techno 
Plastic Products) just before use. 
4.2.1.4 ROS inhibitor, a-tocopherol 
a-tocopherol, a type of vitamin E, was purchased from Sigma-Aldrich Co. 
• • 




4.2.1.5 Cell viability assay reagents 
I. Methvlthiazoletetrazolium (MTT) 
3-(4,5-Dimethyl-2-thiazoly!)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
powder was bought from USB Corporation. 4 mg/ml working solution was prepared 
by dissolving the powder in sterile PBS and stored at 4 °C under subdued light. 
II. Dimethvl sulfoxide (DMSO) 
DMSO was purchased from Sigma-Aldrich Co and stored at room temperature 
in brown bottle. 
4.2.1.6 P-glycoprotein activity assay reagents “ 
I. Rhodamine 123 (Rhl23) 
20 mM rhodamine 123 stock solution was prepared by dissolving Rhl23 
powder (Molecular Probes) in de-ionized water and stored at 4 � C under subdued 
light. 
II. Propidium iodide solution (PI) 
2 mg/ml propidium iodide stock solution was prepared by dissolving PI powder 




4.2.2.1 Cell line propagation and subculture 
SA and Dx5 cell lines were maintained in DMEM supplemented with 10% fetal 
bovine serum (FBS) and 1% v/v antibiotics (PS). The cell lines were cultured in 
75 cm' tissue culture flask (IWAKI) and incubated at a 37。C humidified incubator 
with 5% CO2 supplied. 
For subculture, the medium was discarded and the adherent cells were rinsed 
with pre-warmed PBS. 1.5 ml trypsin-EDTA solution was added and incubated at 
37 °C for 2 min. Complete DMEM was added to cease trypsinization. 
«4 
4.2.2.2 Cell viability assay 
I. Activation of pheophorbide a. the photosensitizer 
To carry out pheophorbide a-mediated photodynamic therapy (Pa-PDT), cells 
were pre-loaded with Pa 2 h before activation. After incubation, the cells were 
irradiated for 20 min using a 600 W quartz-halogen lamp with infra-red irradiation 
attenuated by a layer of water and a colored filter cut-on 610 nm. The light intensity 
was 70 mW/cm- (i.e., 20 min ofirradiation = 84 J/cm"). 
• • 
II. Combination therapy with doxorubicin and Pa-PDT ‘ 
2 X 10^  SA or Dx5 cells were seeded onto each well o f a 96-well culture plate 
• 
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(IWAKI) and incubated for 24 h to allow attachment. The medium was then replaced 
with Dox and/ or Pa of appropriate concentration and incubated for 2 h in dark. Then 
the cells were irradiated by a 600 W quartz-halogen lamp with a filter cut-on 610 nm 
for 20 min. After the photodynamic therapy, the cells were incubated at 37。C for 
another 48 h prior to the evaluation of cell viability. 
III. MTT reduction assay 
Cell culture medium was aspirated and 40 |al MTT solution (4 mg/ml in PBS) 
was added to each well. The plate was incubated for 2 h at 37。C. The MTT solution 
was removed and replaced with 50 i^l DMSO to dissolve the formazan dye formed. 
The absorbance at 540 nm was measured by a microplate reader (Bio-Rad). The 
percentage of cell viability was calculated as follows: 
% viability = [OD540 of test sample/ OD540 of control] x 100% 
4.2.2.3 P-glycoprotein activity assay 
1 X lC)6 cells were seeded on a 60 mm culture dish (IWAKI) for 24 h to allow 
adhesion. Pa of different concentration was added to the cells and incubated at 37 °C 
for 2 h before photo-activation. Immediately after irradiation, 10 i^M Rhl23, the 
•« 
P-glycoprotein substrate, was added to the culture medium. After 2 h incubation, the 
cells were trypsinized and washed with PBS twice. The cell pellets were 
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re-suspended in 5 ^ig/ml PI solution for 15min in room temperature. The samples 
were analyzed by a flow cytometer (BD FACSCanto) and the software MinMDl. 
Internalized Rhl23 and PI were detected by the green and red channel respectively. 
4.2.2.4 Statistical analysis 
Experimental results showed were either representative or averaged data of at 
least 3 independent experiments with consistent results. For cell viability assay, in 
each trail, a mean was obtained from 6 replicates. An average value of means was 
calculated from all 3-4 trials. Therefore the graphical representation was expressed as 
the means of all trials 士 standard error of means (SEM). The difference between 
groups was assessed by one way ANOVA and p-value smaller than 0.05 was 
considered as the minimum criteria for statistical significance. 
The statistical software CalcuSyn (Biosoft) was used to evaluate the 
combination therapy was synergistic, additive or antagonistic. A combination index 





4.3.1 Combination therapy of Pa-PDT and doxorubicin in Dx5 cells 
Multidrug resistant Dx5 cells were treated with Pa-PDT, Dox or a combination 
of both to investigate whether the combination treatment of Pa-PDT and Dox was 
synergistic, additional or antagonistic. MTT assay was performed to determine the 
dose-response of Pa-PDT and Dox. As seen form Figure 4.1，cell viability of Dx5 
decreased with increasing concentration of (A) Pa-PDT, (B) Dox and (C) 
Pa-PDT/Dox. The IC50 of Pa-PDT and Dox after 48 h incubation was found to be 
1.12 and 7.88 i^M respectively. 
The dose-response relationships were analyzed by the software CalcuSyn to 
evaluate whether the combination was synergistic, additive or antagonistic. A 
combination index (CI) of smaller than, equal to and bigger than 1.0 represents a 
synergistic, additive and antagonistic effect respectively. Results suggested that the 
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Figure 4.1 Cytotoxicity of Pa-PDT, doxorubicin and co-treatment of both on 
Dx5 cells. 
»* 
Cell survival was assessed by MTT assay 48 h after the treatment of (A) Pa-PDT, (B) 
Dox and (C) Pa-PDT/Dox. For (C), the combination regimen contained Pa and Dox 
in 1:10 ratio. Each point was expressed as the mean of 4 independent experiments, 
each consisted of 6 replicates 士 SEM. 
Table 4.1 The combination index (CI) between Pa-PDT and doxorubicin in Dx5 
cells. 
Pa i\iM) Dox (^ iM) CI 
0 .2 2 0 . 5 6 8 
0.4 4 0.749 
0 . 6 6 0 . 9 4 6 
0 .8 8 0 . 7 5 2 
1 1^ 0 . 8 8 3 
1.2 n 0.845 -
1.4 U 0 . 8 5 6 
1.6 16 0 . 8 0 3 
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4.3.2 Effect of a-tocopheroI on the synergism between Pa-PDT and doxorubicin 
in Dx5 cells 
The effect of a reactive oxygen species (ROS) inhibitor, a-tocopherol on the 
synergism between Pa-PDT and Dox was investigated in order to determine whether 
the synergism was mediated by ROS. 
As seen in Figure 4.2, the addition of 40 i^M a-tocopherol significantly 
attenuated the cytotoxicity of Pa-PDT, but not the cytotoxicity of Dox. The 
combination index was increased by the addition of a-tocopherol, indicating that the 
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Figure 4.2 Cytotoxicity of Pa-PDT, doxorubicin and co-treattnent of both in the 
presence or absence of 40 ^M a-tocopherol in Dx5 cells. 
Cell survival was assessed by MTT assay 48 h after the treatment of(A) Pa-PDT, (B) 
Dox and (C) Pa-PDTYDox in the presence or absence of 40 ^M a-tocopherol. For (C), 
the combination regimen contained Pa and Dox in 1:10 ratio. Each point was 
expressed as the mean o f 3 independent experiments, each consisted o f 6 replicates 土 
SEM. * P<0.05; ** P<0.01; *** P<0.001, ANOVA. 
Table 4.2 The effect of a-tocopherol on the combination index (CI) between 
Pa-PDT and doxorubicin in Dx5 cells. 
n / i^ /rx ^ / … Combination Index 
Pa (^M) Dox([iM) 
Control 40 i^M a-TocopheroI 
0.5 5 0.894 0.985 
1 ^ 0.879 0.979 厂 
1.5 U 0.807 0.928~~-
2 20 0.816 0.928 
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4.3.3 Effect of Pa-PDT on P-glycoprotein activity in Dx5 cells 
In order to validate the involvement of P-gp in the synergism, the effect of 
Pa-PDT on P-gp activity was investigated. Dx5 cells were first treated with Pa-PDT 
of different concentrations, then the intracellular accumulation of the P-gp substrate 
rhodamine 123 (Rhl23) was estimated by the green fluorescence emitted. Membrane 
integrity was detected by staining with propidium iodide (PI), which is impermeable 
to cells with intact plasma membrane. 
The green and red fluorescence of Rhl23 and PI were detected by flow 
cytometry and results were shown in Figure 4.3. The quadrant 4 population (cells 
with intact plasma membrane and increased Rh 123 internalization) increased 
dose-dependently with Pa-PDT, indicating that Pa-PDT was able to reduce P-gp 
activity without compromising membrane integrity. Quadrant 2 denotes cells with 
damaged plasma membrane, thereby became permeable to PI. Population of quadrant 
2 increased dose-dependently with Pa-PDT, but it remained the minority of the 
population. When cells were co-treated with 100 i^M anti-oxidant a-tocopherol, the 
quadrant 2 and 4 populations were remarkably reduced, indicating that the effect of 
Pa-PDT was attributed by the generation of intracellular ROS. For dark control with 
•« 
1 i^M Pa without irradiation, the majority of cells remained in quadrant 3，indicating 
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Percentage of population 
Concentration (uM) ; 
Quadrant 1 Quadrant 2 Quadrant 3 Quadrant 4 
0 0.2 ^ ^ 3.8 
0.25 0.0 [ ^ ^ 11.8 
Pa-PDT 0.5 0.1 ^ 68.7 28.8 
0.75 0.1 ^ 54.8 39.8 
1 ^ n ^ 4 ^ 48.4 
Pa-PDT & 100 i^M 0.5 0.1 ^ ^ 9.4 
a-Tocopherol 1 ^ 52 55.9 38.8 
Pa Dark Control 1 1.2 1.4 96.9 0.5 
n 
Figure 4.3 Effect of Pa-PDT on P-glycoprotein activity in Dx5 cells. 
Dx5 cells were treated with (A-E) 0-1 i^M Pa-PDT, (F, G) 100 ^M a-tocopherol and 
0.5 or 1 i^M Pa-PDT and (H) 1 ^ iM Pa only without PDT. Cells were then co-stained 
with rhodamine 123 and propidium iodide. The green and red fluorescence were 
detected simultaneously by flow cytometry. 
Quadrant 4 denotes cells with reduced P-gp activity and intact plasma membrane and 
quadrant 2 denotes cells with damaged plasma membrane. Percentage of population 




4.3.4 Combination therapy of Pa-PDT and doxorubicin in SA cells 
Similar combination therapy was tested on SA, the parental cell line of Dx5. 
MTT assay was performed to determine the dose-response of Pa-PDT and Dox. As 
seen form Figure 4.4, viability ofSA cells decreased with increasing concentration of 
(A) Pa-PDT, (B) Dox and (C) Pa-PDT/Dox. The IC50 ofPa-PDT and Dox after 48 h 
incubation was 0.93 and 0.68 i^M respectively. 
The dose-response relationships were analyzed by the software CalcuSyn to 
evaluate whether the combination was synergistic, additive or antagonistic. A 
combination index (C1) of smaller than, equal to and bigger than 1.0 represents a 
synergistic, additive and antagonistic effect respectively. Experimental results 
showed that the combination ofPa-PDT and Dox was generally antagonistic at lower 
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Figure 4.4 Cytotoxicity of Pa-PDT, doxorubicin and co-treatment of both on SA 
cells. 
Cell survival was assessed by MTT assay 48 h after the treatment of (A) Pa-PDT, (B) 
Dox and (C) Pa-PDT/Dox. For (C), the combination regimen contained Pa and Dox 
in 1:1 ratio. Each point was expressed as the mean of 4 independent experiments, 
each consisted of 6 replicates 士 SEM. 
Table 4.3 The combination index (CI) between Pa-PDT and doxorubicin in SA 
cells. 
Pa (^ iM) Dox (^ iM) CI 
0.2 ^ 0.964 
0.4 M 1.365 
0.6 ^ 1.252 
0.8 0^ 1.144 
1 1 0.978 ” 
1.2 U 0.997 . 
1.4 \_A 0.792 
1.6 \_^ 0.938 
• 
1 4 0 
4.4 Discussion 
There are clinical limitations for the chemotherapy with doxorubicin and 
photodynamic therapy in treatment cancers. For instance, prolonged use of 
doxorubicin is prone to cardiotoxicity and development of multidrug resistance 
(Longley and Johnston 2005; Gilleron et al. 2009). And the risk of relapse restricted 
the use of PDT in deep and refractory tumors (Sinha et al. 2006). Therefore, new 
treatment approaches are needed to improve the efficacies of both treatments for 
more satisfactory clinical outcome, ln this study, a novel combination treatment that 
utilizes chemotherapeutic drug Dox and Pa-PDT was demonstrated on uterine 
sarcoma cell lines. “ 
Figure 4.1 demonstrated the dose-dependent decrease in cell viability by 
Pa-PDT, Dox alone and the combination of both agents. The IC50 of Pa-PDT and 
Dox was 1.12 and 7.88 i^M respectively. Combination index (CI) was calculated by 
the software CalcuSyn to determine the nature of the combined treatment. A 
combination index (CI) of smaller than, equal to and bigger than 1.0 represents a 
synergistic, additive and antagonistic effect respectively. Results indicated the 
anti-proliferative effect of Dox combined with Pa-PDT against MDR uterine sarcoma 
• ” 
Dx5 cells was synergistic at all tested dose range according to the CI values as shown 
inTable4.1. 
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The synergism observed proved the therapeutic potential of Pa-PDT and Dox as 
combination regimens for the treatment of MDR uterine sarcomas. Synergism of 
combination therapy implied better local control of tumor, as well as the palliation of 
side-effects by the reduction of Dox dosage required to achieve the same extent of 
treatment satisfaction. The synergistic effect was more prominent in lower dose of 
Pa-PDT/ Dox (0.2 / 2 i^M and 0.4 / 4 i^M) indicated by the smaller values of CI and 
this result is of particular clinical relevance. In general, anti-neoplatic agents usually 
have very narrow therapeutic window. Although drug resistant cancers require a very 
high dose of chemotherapeutic drugs to be eradicated, such dosage may cause 
non-manageable side-effect so is unlikely to be prescribed (L^ge 2008). So any 
agents that can serve as a combination regimen with low dose Dox in a synergistic 
way would be especially beneficial for patients suffering from MDR malignancies. 
The general mechanism of PDT involved the generation of intracellular reactive 
oxygen species (ROS) upon light irradiation (Golab et al. 2003). Previous work has 
demonstrated the elevation of intracellular ROS level after Pa-PDT and the 
attenuation of Pa-PDT cytotoxicity by anti-oxidant in hepatocarcinoma cell line 
•« 
Hep3B (Tang et al. 2006). ln order to investigate whether the synergistic effect of 
Pa-PDT/Dox combination therapy was mediated by the generation of ROS, the effect 
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of a ROS scavenger a-tocopherol on the synergism was investigated. As seen in 
Figure 4.2, the cell viability of Pa-PDT was significantly increased by the presence 
of the anti-oxidant a-tocopherol owing to the fact that the cytotoxicity of Pa-PDT 
was mainly mediated by the generation of ROS. Therefore, cytotoxicity would be 
abolished by the reduction in ROS generation. 
ln contrast, the cytotoxicity of Dox was not abrogated by a-tocopherol. 
Although previous researches showed that the Dox-derived semiquinone free radicals 
contributed to the cardiotoxic and maybe, partly the anti-neoplastic property of Dox 
(Doroshow et al. 1981; Olson et al. 2003; Gilleron et al. 2009), broad spectrum 
anti-oxidants failed to scavenge such free radicals nor to preverit the action of Dox 
(Simunek et al. 2009). Therefore a-tocopherol, a kind of anti-oxidant vitamin E, 
could not attenuate the cytotoxicity ofDox to Dx5 cells. 
As seen in Table 4.2, the combination index was elevated in the presence of 
40 i^M a-tocopherol in all tested range of combination regimens, meaning that the 
synergism between Pa-PDT and Dox was attenuated by the anti-oxidant 
a-tocopherol. It suggested that the synergism was mediated by intracellular ROS 
generation. As previous works have demonstrated that the expression of the 
«• 
multidrug resistance-associated ABC transporter P-glycoprotein (P-gp) was 
suppressed by elevation of ROS level via the activation of JNK or p38MAPK 
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pathway (Gibson et al. 1995; Wartenberg et al. 2001; Droge 2002; Wartenberg et al. 
2005; Cai et al. 2007; Klamt et al. 2008)，therefore the effect of Pa-PDT on P-gp 
activity was investigated. Immediately after Pa-PDT treatment, Dx5 cells were 
stained by rhodamine 123 (Rhl23), a P-gp substrate and propidium iodide (PI), a 
DNA dye which is impermeable to intact cells. Rhl23 and PI exhibit green and red 
fluorescence respectively upon excitation, potentiating co-staining and 
simultaneously detection. 
Referring to Figure 4.3，Quadrant 3 indicates cells with low green and red 
fluorescence, implying that they have high P-gp activity and intact plasma membrane. 
Quadrant 4 denotes the cells with elevated Rhl23 internalization* caused by reduced 
P-gp activity, yet the plasma membrane remains intact to exclude P1. Quadrant 2 
refers to the cells with damaged plasma membrane, thereby became permeable to PI, 
as a result the cells exhibit high intracellular R123 and PI accumulation. 
Results revealed that quadrant 4 population increased dose-dependently with 
Pa-PDT (Figure 4.3 A-E), demonstrating the ability of Pa-PDT in reducing P-gp 
activity without compromising membrane integrity. Quadrant 2 was not the 
dominating population, yet it increased dose-dependently with Pa-PDT, indicating 
Pa-PDT can cause plasma membrane disruption to certain extent. In the presence of 
100 i^M anti-oxidant a-tocopherol (Figure 4.3 F-G), quadrant 2 and 4 populations 
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were remarkably reduced, indicating that the effect of Pa-PDT was attenuated by the 
suppressed ROS generation. It was consistent with previously founding revealing the 
down-regulation of P-gp by elevated ROS level. However, there was one major 
limitation in this experiment. Although a-tocopherol does not share structural 
similarity with common P-gp substrates and therefore competitive inhibition is 
unlikely to occur, a-tocopherol has been suggested to possess non-antioxidant roles 
as a signaling molecule (Zingg and Azzi 2004). In order to confirm the involvement 
ofROS generation in the attenuation of P-gp activity, the assays can be repeated with 
cells pre-loaded with ROS scavengers other than a-tocopherol before Pa-PDT. 
No significant change in P-gp level nor membrane integrity ^vas observed in the 
dark control of 1 ^ iM Pa (Figure 4.3 H), indicating the above mentioned effects could 
not be accomplished without photo-activation. The general upward shifting after Pa 
treatment was attributed by the fact that Pa exhibits red fluorescence upon excitation. 
The above results suggested when Dx5 cells were subjected to Pa-PDT, the 
activity of P-gp was attenuated although the plasma membrane remained intact, 
indicating that the inactivation of P-gp was a specific event instead of a global 
damage to plasma membrane. Therefore the MDR Dx5 cells were sensitized and 
•« 
became more vulnerable towards the cytotoxicity of Dox, resulting in the synergism 
observed in the macroscopic view. 
145 
The combination therapy was also tested on the parental cell line of Dx5, 
namely, the Dox sensitive MES-SA (SA). As seen in Figure 4.4, viability of SA cells 
decreased with increasing concentration of Pa-PDT, Dox and Pa-PDT/Dox. The IC50 
of Pa-PDT and Dox was 0.93 and 0.68 i^M respectively. The dose-response 
relationships were analyzed by the software CalcuSyn to evaluate whether the 
combination was synergistic, additive or antagonistic. Experimental results showed 
that the combination of Pa-PDT and Dox was generally antagonistic at lower dose, 
and turned to be additive or weakly synergistic at higher dose. It implied that the 
synergism between Pa-PDT and Dox observed in MDR Dx5 cells was not exhibited 
in the parental, non-MDR SA cells. As discussed above, the synergism was mediated 
by the attenuation of P-gp activity and thus chemo-sensitization towards Dox. 
Therefore, owning to the low expression level of P-gp in SA cells (Data referred to 
Section 3.3.2), such synergism cannot be manifested. 
When comparing Figure 4.1 and 4.4, results indicated although MDR Dx5 cells 
exhibited remarkable Dox resistance compared with the parental SA cells (IC50 of 
Dox was 7.88 |aM in Dx5 while 0.68 |iM in SA), the cytotoxicity of Pa-PDT on both 
cell lines was similar (IC50 ofPa-PDT was 1.12 ^M in Dx5 while 0.93 i^M in SA). It 
«• 
implied that Pa-PDT could circumvent the P-gp mediated MDR in Dx5 cells. • 
“ 146 
This present study demonstrated that the new combination therapy of Pa-PDT 
and Dox was synergistic in MDR uterine sarcoma cell line Dx5, and the synergism 
was attributed by the attenuation of P-gp activity mediated by the generation ofROS. 
The results provided an insight towards the feasibility of combination regimens in 
enhancing the efficacies of different treatment approaches, for instance, 
chemotherapy and photodynamic therapy. This combination has particularly high 
therapeutic potential, because it captures the advantage of PDT as a local treatment, 
as well as the systemic chemotherapy to prevent the recurrence of the disease. 
Patients are likely to be benefited by the lower systematic side-effects and reduced 
risk of relapse. “ 
However, result suggested that the combination regimens of Pa-PDT and Dox 
should be recommended for MDR uterine sarcomas, but not Dox-sensitive 
counterpart, as synergism was observed in the MDR Dx5 cells only, but not the 
parental SA cells, lt was demonstrated that the synergism was mediated via P-gp 
inactivation caused by the elevation of intracellular ROS level during PDT. Therefore 
such synergism could not be exhibited in non-P-gp over-expressing SA cells. Besides, 
the lC50 ofPa-PDT was found similar in both parental and MDR cell lines, reassured 
«« 









The goal for successful cancer treatment is the complete removal of cancer cells 
with minimal toxicity towards normal tissues. Photodynamic therapy (PDT) is an 
emerging localized cancer modality offering potential efficacy of tumor clearance 
with high patient tolerability and brief treatment duration (Marmur et al. 2004). 
Pheophorbide a (Pa), a photosensitizer originally isolated from the Chinese herbal 
medicine Scutellaria barbata, demonstrated anti-cancer effects on various cell types 
upon photo-activation (Chan et al. 2006; Busch et al. 2009). In order to further 
evaluate the potential of Pa-mediated photodynamic therapy (Pa-PDT) as anti-cancer 
regimen, the mechanisms involved in the anti-proliferative effect of Pa-PDT and its 
relationship with multidrug resistance were investigated in this study. 
5.1 Pa-PDT induced growth arrest and DNA fragmentation in breast cancer 
MCF-7 cells 
Induction of the growth arrest and DNA damage inducible (GADD) genes 
including GADD34, GADD45A, GADD45G and GADD153 was demonstrated 24 h 
after Pa-PDT in the human breast cancer cell line MCF-7. The mRNA level of 
GADD45B was not significantly altered. A time and dose-dependent G2/M phase cell 
_ 
cycle arrest was observed 24 h onwards after Pa-PDT while the dose-dependent • 
sub-Gi population dominated the cell cycle profiles at 72 h after Pa-PDT. Protein 
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levels of cyclin B1 and D1 was reduced by Pa-PDT dose-dependently while that of 
cyclin A and E was not significantly altered. 
The above results suggested that the photo-activation of Pa caused DNA and 
cellular damage in MCf-7 cells and subsequently the induction ofGADD genes. The 
up-regulation of GADD genes and down-regulation of cyclin B1 and D1 orchestrated 
the G2/M cell cycle arrest, which aims at providing time for cellular repair as the 
cell's own protective mechanism. Since the damage was irreversible, the cells 
eventually proceed to the death pathway as detected by DNA fragmentation. It 
confirmed the potent anti-cancer effect of Pa-PDT via the reinforcement of the 
intrinsic cycle regulation, apart from the immediate apoptotic response observed in 
other cell lines. The involvement of multiple pathways suggested that Pa-PDT 
remains potent towards cancer cells with mutated death pathway mediators or 
effectors, for instance, the absence of caspase 3 in MCF-7 cells. Moreover, 
reinforcement of cycle regulation suggests genomic fidelity and may reduce the 
chance of mutation, thus reducing tumorigenicity and the chance of multidrug 




5.2 Circumvention of doxorubicin resistance by Pa-PDT in breast cancer MDA 
cells 
The establishment of a multidrug resistance (MDR) breast cancer cell line was 
attempted in order to provide an in vitro model for evaluating the potential of 
Pa-PDT in circumventing MDR cancers. The parental cell line chosen was 
MDA-MB-231 (MDA), an estrogen receptor negative breast adenocarcinoma cell 
line representing a late stage of disease. After 10 rounds of doxorubicin (Dox) 
treatment with concentration ranging from 0.1 to 2 i^M, Dox tolerability was 
increased and intracellular Dox accumulation was reduced. The acquisition of Dox 
resistance did not confer the resistance to Pa-PDT, as the cytotox4city of Pa-PDT was 
demonstrated similar in both MDA and MDA-R cells and the extent of Pa uptake did 
not differ significantly. Results suggested that Pa-PDT was able to circumvent the 
Dox resistance acquired by repeated drug exposure in MDA cells. 
5.3 Synergistic anti-proliferation of Pa-PDT and doxorubicin on uterine 
sarcoma cell line Dx5 
Photodynamic therapy and chemotherapy and have their own clinical limitations, 
«• 
for example the effectiveness of PDT is often limited by the shallow tissue • 
penetration of light and risk of relapse in large or refractory tumors (Marmur, 
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Schmults et al. 2004). The clinical effectiveness of chemotherapy is limited by its 
side-effects and the development of multidrug resistance may cause treatment failure 
(Longley and Johnston 2005). In this study, the therapeutic potential of a novel 
combination treatment that utilizes chemotherapeutic drug Dox and Pa-PDT on a 
MDR cell line was investigated. As the MDA-R cell line developed as described 
above was only mildly resistant to Dox, a commercially available MDR, 
P-glycoprotein (P-gp) over-expressing uterine sarcoma cell line Dx5 was chosen as 
the in vitro model. 
Results demonstrated the synergistic combination treatment of Pa-PDT and Dox 
in Dx5 cells. P-gp substrate Rhl23 and PI co-staining result showed that Pa-PDT 
attenuated P-gp activity without severe damage to plasma membrane integrity. The 
MDR Dx5 cells were thereby sensitized and became more vulnerable towards the 
cytotoxicity of Dox, resulting in the synergism observed in the macroscopic view. 
The synergism and inhibition of P-gp activity was showed to be attenuated by the 
anti-oxidant a-tocopherol, suggesting that the synergism was mediated by the 
reduction of P-gp activity via the generation of reactive oxygen species (ROS). Such 
synergism, however, was not observed in the parental, Dox sensitive cell line SA. As 
«• 
SA has very low intrinsic expression ofP-gp, such synergism could not be exhibited.. 
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5.4 Clinical implications 
The pursuit of more selective therapeutic approaches has attracted extensive 
research in recent years. As a localized treatment, photodynamic therapy does not 
cause severe systemic side-effects, which is commonly experienced by patients 
undergoing chemotherapy, ln this study, the potential of pheophorbide a (Pa) in 
serving as a photosensitizer for PDT was being evaluated. As Pa possesses a longer 
excitation wavelength compared to the currently available photosensitizers, it is 
potentially advantageous by offering deeper tissue penetration. 
It was shown that Pa-PDT induced cell death in p53 negative human breast 
tumor cell line MCF-7 via cell cycle arrest and direct induction of apoptosis. The 
involvement of multiple death pathways suggested that Pa-PDT would remain potent 
in tumors with mutated death signaling modulators, which is commonly observed in 
human cancers. Besides, the combination regimen with Pa-PDT and Dox was 
demonstrated to be synergistic in MDR cell line Dx5, attributed by the potency of 
Pa-PDT in inhibiting P-gp activity. It provided insights towards the development of 
novel strategies in reversing P-gp mediated MDR. 
• • 
5.5Conclusions and future perspectives • 
Pa-PDT induced a time and dose-dependent Go/M phase cell cycle arrest and 
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subsequently DNA fragmentation in MCF-7 cells. The growth arrest was mediated 
by the induction of GADD genes and down-regulation of cyclin B1 and D1. Some 
researchers demonstrated the involvement of cAMP-dependent protein kinase (PKA), 
p38 MAPK, JNK and ER stress signaling pathways in the GADD genes-mediated 
cell cycle arrest and apoptosis (Carrier et al. 1998; Sutter et al. 2003; Liebermann 
and Hoffman 2008; Watanabe et al. 2008). The actual pathway initiated by Pa-PDT 
in MCF-7 cells can be further investigated by Westem blot analysis and specific 
inhibitors of various pathways. 
In the attempt of multidrug resistance development in MDA cells, 10 rounds of 
Dox treatments resulted in 3 fold increase in drug tolerability. The potential of 
Pa-PDT in circumventing such resistance was demonstrated, since the toxicity and 
drug accumulation was not remarkably reduced in MDA-R cells. The Dox resistance 
acquired was rather weak and the possible causes were discussed in Chapter 3. As a 
future work, other approaches, for instance, persistent instead of intermittent Dox 
exposure can be attempted. After a stable MDR cell line is established, the 
mechanisms involved can be characterized by 2D gel electrophoresis or mRNA 
• • 
microarray analysis as follow up work. • 
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The anti-proliferative effect of the combination regimen with Pa-PDT and Dox 
was shown to be synergistic on the MDR cell line Dx5 but such synergism was 
absent in the parental cell line SA. Pa-PDT reduced the activity of P-gp and thereby 
sensitized Dx5 cells towards the cytotoxicity of Dox. The synergism and P-gp 
activity inhibition were attenuated by the ROS scavenger a-tocopherol, suggesting 
the involvement of ROS generation. Further elucidation of the pathways involved in 
the P-gp activity inhibition can provide insight in new strategies towards 
chemo-sensitization of multidrug resistant cancers. 
The anti-proliferative effect of Pa-PDT has been demonstrated potent in various 
cancer cell types, ln order to evaluate the clinical anti-caner potential of Pa-PDT, 
more in vivo assays have to be done. It was previously found that Pa-PDT 
demonstrated no significant cardiac and liver toxicity in tumor-bearing nude mice 
(data not published), but the in vivo pharmacokinetics of Pa has to be well studied 
before proceeding to any clinical trails. The ADEM properties ofPa, which refers to 
the absorption into blood circulation, distribution throughout the entire body, 
metabolism involved and excretion of the substance, should be elucidated to estimate 
«• 
the dosage required for satisfactory treatment outcome, duration required for. 
assimilation before photodynamic activation and the degree of tumor specificity. 
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Modification in the irradiation devices is another research direction for 
photodynamic therapy. Medical laser light source is used in the clinical settings to 
provide the monochromatic and intense illumination to lesion area. In recent years, 
some researches suggested the application of two-photon activation in photodynamic 
therapy. The wavelength required for two-photon excitation of the same 
photosensitizer is longer than the conventional single-photon excitation, implying a 
deeper tissue penetration (Liu et al. 2002; Fisher et al. 2009). Improvement in light 
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